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Abstract
Significance: Macrophages are crucial for tissue homeostasis. Based on their activation, they might display
classical/M1 or alternative/M2 phenotypes. M1 macrophages produce pro-inflammatory cytokines, reactive
oxygen species (ROS), and nitric oxide (NO). M2 macrophages upregulate arginase-1 and reduce NO and ROS
levels; they also release anti-inflammatory cytokines, growth factors, and polyamines, thus promoting angio-
genesis and tissue healing. Moreover, M1 and M2 display key metabolic differences; M1 polarization is char-
acterized by an enhancement in glycolysis and in the pentose phosphate pathway (PPP) along with a decreased
oxidative phosphorylation (OxPhos), whereas M2 are characterized by an efficient OxPhos and reduced PPP.
Recent Advances: The glutamine-related metabolism has been discovered as crucial for M2 polarization. Vice
versa, flux discontinuities in the Krebs cycle are considered additional M1 features; they lead to increased levels
of immunoresponsive gene 1 and itaconic acid, to isocitrate dehydrogenase 1-downregulation and to succinate,
citrate, and isocitrate over-expression.
Critical Issues: A macrophage classification problem, particularly in vivo, originating from a gap in the
knowledge of the several intermediate polarization statuses between the M1 and M2 extremes, characterizes this
field. Moreover, the detailed features of metabolic reprogramming crucial for macrophage polarization are
largely unknown; in particular, the role of b-oxidation is highly controversial.
Future Directions:Manipulating the metabolism to redirect macrophage polarization might be useful in various
pathologies, including an efficient skeletal muscle regeneration. Unraveling the complexity pertaining to
metabolic signatures that are specific for the different macrophage subsets is crucial for identifying new
compounds that are able to trigger macrophage polarization and that might be used for therapeutical purposes.
Antioxid. Redox Signal. 00, 000–000.
Keywords: metabolic reprogramming, macrophage polarization, cross-talk muscle-macrophages, skeletal
muscle regeneration, rehabilitation, mitochondria
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I. Introduction
Macrophages (MF) are inflammatory cells with ahigh capacity for engulfing and digesting pathogens
and cell debris. In addition, MF play increasingly defined
roles in orchestrating the healing of various damaged tissues
and show high heterogeneity, plasticity, and adaptation
abilities. Based on their environment and on the activation of
specific signaling pathways, they might display, schemati-
cally, a pro-inflammatory (M1) or an anti-inflammatory
(M2) phenotype, which will hereby be described. Differen-
tially activated MF also show diverse metabolic features,
with a link between the metabolic pathways operating in MF
and their pro-/anti-inflammatory status; this review will focus
on the potentiality of manipulating metabolism to polarize MF.
Among the various tissues in which MF play a role, their
effect on skeletal muscle will be emphasized; differentially
activated MF are crucial for efficient muscle regeneration by
means of a complex cross-talk with skeletal muscle resident
cells. Specifically, MF polarization can be metabolically
modulated to improve the regenerative process; this aspect
will be highlighted, with special focus on therapeutical ap-
proaches.
II. MF: Origin and Fate
MF represent one of the body’s first lines of defense
against pathogens. First described in 1887 by Metchnikoff as
a population of phagocytes with the capacity to engulf and
kill pathogens, MF are long-living cells of the innate immune
system that also play a central role in adaptive immunity (156).
They are present in all organs and tissues and can assume
different phenotypes and functions; their diversity depends
both on their origin and on the tissue and extracellular mileu
in which they are located.
A. Origin
Most tissue MF derive from circulating monocytes ex-
travasating from the bloodstream into injured tissues where
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they differentiate into MF (8). MF are characterized by the
expression of markers, including CD45, the colony-
stimulating factor 1 (CSF1)-receptor (CSF1R), CD11b, and
the GPCR F4/80, none of which are uniquely restricted to
MF. Depending on the tissue, MF can express different
markers associated to their function in that tissue and can also
assume different names (Fig. 1).
The study of MF ontogeny in mice showed that monocytes
andMF derive fromMF and dendritic cell progenitors (MDPs),
which are bone marrow resident hematopoietic stem cells
(c-kit+CX3CR1+Flt3+CD115+) (95). MDPs differentiate into a
common monocyte precursor (c-kit+CX3CR1+Flt3-CD115+),
which gives rise to the two main subsets of circulating
monocytes, distinguished, in mice, by the expression of Ly6C
and the chemokine receptor CX3CR1; Ly6C+CX3CR1low are
considered pro-inflammatory monocytes homing to inflamed
tissues, whereas Ly6ClowCX3CR1high monocytes are less
abundant and home to noninflamed healthy tissues contribut-
ing to tissue repair (102).
Most MF derive from circulating monocytes, whereas
some tissue-resident MF arise from a distinct mechanism of
hematopoiesis. For example, microglia is ontogenetically
distinct from bone marrow-derived MF (BMDM), as it de-
rives from yolk sac mesenchymal progenitors, which early in
mouse embryo development migrate to the neuroepithelium
without passing through a monocytic stage (105). Indeed,
during mammal embryogenesis, hematopoiesis takes place in
different organs (mainly yolk sac and fetal liver) before the
hematopoietic stem cells establish in the bone marrow.
The first hematopoietic cells arising in mice are mesen-
chymal progenitors appearing at E7.5 in the yolk sac. These
precursors generate erythrocytes and MF but not lympho-
cytes. Around E8.5, progenitors from the yolk sac begin to
seed into the fetal liver and start the first wave of hemato-
poiesis. A second wave starts at E10.5 and takes place in the
major arterial vessels of the aorta-gonad-mesonephros re-
gion. Clusters of hematopoietic precursors with endothelial
features, once they are passed through different stages, give
FIG. 1. Different phenotypes and specialized functions of MF in different organs and tissues. Graphical schema-
tization of tissue-specific MF. MF are spread throughout the body, in all tissues and organs. MF in different compartments
share some common features, expression markers, and functions (indicated in central panel). The perimeter panels describe
tissue-specific MF with different names specific for each organ; in some cases, as in bone and spleen, different types of MF
can be found in the same organ. For each MF type, a list of specific expression markers (surface markers or transcription
factors) is provided, together with a summary of the main organ-specific functions. MF diversity is also highlighted by
tissue-specific names: osteoclasts in the bones, Kupffer cells in the liver, microglia in the brain, alveolar MF in the lung,
marginal-zone and red-pulp MF in the spleen, and subcapsular sinus and medullary MF in lymph nodes. MF, macrophages.
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rise to the definitive hematopoietic stem cells that are able
to differentiate into multiple lineages (336). After E16.5,
the transition to the bone marrow—the definitive site of
hematopoiesis—takes place.
Besides microglia, long-lived embryonic precursors per-
sist during adulthood and contribute to other resident MF in
murine adult tissues—such as Kupffer cells in the liver or
alveolar MF in the lung—whereas MF in other tissues are
replaced. Thus, at least in mice, two ontogenetically distinct
MF populations persist in adults, the ones derived from the
bone marrow and the ones derived from the yolk sac. The
latter population proliferate and sustain their presence in vivo
independently of bone marrow-derived monocytes. Indirect
evidence suggests that also in humans, some tissue MF are
long-lived cells existing independently of circulating mono-
cytes (269).
B. Activation/polarization
MF are phagocytes that respond to danger signals, sensing
injury and infection; activated MF engulf and digest invad-
ing and damaged cells. They also present the antigen to
lymphocytes and produce cytokines, thus further enhancing
inflammation. In addition, MF are crucial for tissue ho-
meostasis (232, 312); indeed, depending on their activation
and on their microenvironment, MF might play pro-
inflammatory or anti-inflammatory roles, thus leading to a
gross classification into two groups: M1 and M2 (198, 213).
M1 are obtained by ‘‘classical’’ activation; they remove
foreign and damaged cells thanks to their highly bactericidal
and phagocytic capacity. Conversely, M2, obtained by ‘‘al-
ternative’’ activation, resolve inflammation and mediate tis-
sue regeneration and angiogenesis. MF are plastic cells that
readily switch their phenotype. With a wide-ranging agree-
ment among scientists, the acquisition of different pheno-
types by MF is referred to as polarization (189, 196, 234).
1. M1 polarization. M1 polarization is elicited by
interferon-c (IFNc) priming associated to pro-inflammatory
cytokines, for example, tumor necrosis factor-a (TNFa), or
by Toll-like receptor (TLR) ligands such as microbial prod-
ucts like pathogen-associated molecular patterns (PAMPs) or
opsonins. PAMPs are molecules binding to TLRs that are
highly conserved in different classes of pathogens, for ex-
ample, lipopolysaccharide (LPS)—a component of the
Gram-negative bacterial membrane—binding TLR4. LPS is
commonly used to induce M1 activation in vitro. Other
PAMPs are flagellin, peptidoglycans, and viral double-
stranded RNA.
The activation of TLRs, together with NOD-like receptors,
by PAMPs as well as by danger-associated molecular patterns
(DAMPs) from the damaged tissue or by alarmins leads to M1
polarization. DAMPs are small molecules that are highly
concentrated within healthy cells but absent or rare in the ex-
tracellular matrix (ECM), such as the high mobility group box
1 (HMGB1) protein regulating chromatin organization in
healthy cells, nucleotides (ATP, ADP, UDP), oxidized phos-
pholipids, heat shock proteins, and uric acid (224).
DAMPs are rapidly released after unprogrammed cell
death, and they bind pattern recognition receptors (PRRs) on
the immune cells’ surface that become activated and start the
inflammatory response. PRRs binding DAMPs might either
be the same as those binding PAMPs (e.g., TLR) or be unique
for DAMPs, such as RAGE (receptor for advanced glycation
end products) binding HMGB1 or purinergic (P2) receptors
sensing extracellular nucleotides, such as P2X7. MF acti-
vation by DAMPs occurs in case of sterile inflammation,
meaning in the absence of pathogens like in muscle injury,
where cellular debris triggers M1 polarization.
Differentially activated MF subsets might be identified
by the spectrum of secreted soluble factors. Briefly, M1
produce antiviral proteins, pro-inflammatory cytokines, and
chemokines (Fig. 2) [for review see Mortha and Burrows
(223)]; high amounts of reactive oxygen species (ROS) and
nitric oxide (NO), the latter mainly by inducible NO syn-
thase (iNOS), which is considered among the most reliable
markers of M1 activation (see section IV.C) (224, 280). M1
are characterized by an increased killing rate and antigen
presentation ability (224). In addition, some cell surface mol-
ecules highly expressed in M1 compared with unstimulated
MF (M0) or M2 are used as M1 polarization markers
(Fig. 2) (373).
However, the high degree ofMF plasticity and their ability
to switch from a phenotype to another, through intermediate
polarization status, makes the identification of unambiguous
membrane markers distinguishing M1 from M2 difficult.
Indeed, differently polarized MF can be better identified by
also considering the pattern of cytokines and chemokines
secreted, the effect exerted on surrounding tissues, and their
metabolic status (see section IV) (313).
2. M2 polarization. On the other hand, M2 phenotypical
activation is favored in normal tissue homeostasis and during
recovery of tissues after damage, where M2 are necessary to
resolve the inflammatory response and to allow tissue healing
and remodeling. Anti-inflammatory and regenerative M2
produce interleukin (IL)-10, IL-1ra (IL-1 antagonist), growth
factors, and polyamines (Fig. 2), which stimulate fibroblast
growth, collagen, and production of ECM components, thus
promoting fibrosis, angiogenesis, lymphangiogenesis, and
damaged tissue healing.
M2 also play a role in parasite infection and tumor pro-
gression (114, 382). ROS production is reduced in M2 and
arginase-1 (Arg1) is upregulated, thus also lowering NO
production. By secreting IL-10, which inhibits T helper (Th)1
lymphocytes and inflammatory cytokine production, and by
recruiting regulatory T cells in damaged sites, M2 directly
contribute to dampen inflammation; in fact, inflammation is
necessary for protection against infections, but if prolonged,
it might cause tissue damage (148).
M2 activation is fostered by anti-inflammatory, pro-
tolerogenic Th2 cytokines such as IL-10, IL-4, and IL-13;
whereas it might be inhibited in a context in which Th1/Th17
cytokines dominate. Macrophage colony-stimulating factor
(M-CSF), systemically expressed and crucial for MF dif-
ferentiation from precursor cells, can also prime and support
M2 polarization (although not acting by itself) by inducing
the expression of M2-associated genes (Fig. 2) together with
cell cycle regulatory genes (cyclins) that foster homeostatic
proliferation (199, 287). The broad availability of M-CSF
contributes to maintaining the pool of tissue residentM2 (67).
M2 upregulate Arg1 and activate the arginine pathways,
producing ornithine and polyamines (see section IV.C.2). As
NO and ornithine are directly involved in pathogen killing,
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angiogenesis, and tissue repair, these molecular signatures
are considered the most typical features of M2 activation
(212). Cell surface molecules over-expressed in M2 and used
as their markers are indicated in Figure 2 and reviewed by
R}oszer (198, 287). Notably, many of the reported M1 andM2
markers are not specific for MF but are also expressed by
other cell types.
M2 have a high degree of heterogeneity and a further clas-
sification into three subgroups—M2a, M2b, and M2c—has
been proposed, mainly on the basis of the inducing stimuli and
on the panel of secreted factors (195). All three M2 subtypes
are characterized by high IL-10 and low IL-12 levels.
M2a—where ‘‘a’’ stands for ‘‘alternative’’—are induced
by IL-4/IL-13 stimulation; they produce high levels of IL-10
and IL-1ra and express the mannose receptor CD206 and the
receptor IL-1RII, a nonsignaling molecule that acts as a de-
coy receptor for IL-1. M2a are involved in Th2 responses,
allergy, and the killing and encapsulation of parasites (195).
M2b are induced by exposure to immunocomplexes and
agonists of IL-1R or TLRs such as LPS, thus displaying a pro-
inflammatory cytokine profile, as they produce, together with
IL-10, discrete amounts of IL-6 and TNFa but a very low
amount of IL-12. As discussed later, similar to M1, M2b do
not express high levels of Arg1, which is a marker for M2a
and M2c (195).
M2c are induced by IL-10 and glucocorticoid hormones
and are also referred to as ‘‘deactivated’’ MF. M2c express
CD206, produce Arg1, and secrete IL-1ra, IL-10, and trans-
forming growth factor-b (TGF-b). Moreover, they also ex-
press CD163, which is not expressed by other M2 subtypes
(158). M2c are involved in tissue remodeling, ECM deposi-
tion, and immunoregulation (195). Interestingly, under the
effect of IL-10, they express discrete amounts of CCR2 and
CCR5 receptors for pro-inflammatory chemokines (MCP1/
CCL2, RANTES/CCL5, macrophage inflammatory protein
(MIP)1a/CCL3, and MIP1b/CCL4), which, in a mileu rich in
IL-10, would serve as a scavenger receptor system to dampen
inflammation (270).
Additional MF phenotypes have been more recently
identified; some of them—namely Mox, M(Hb), Mhem, and
M4—have been described in the atheresclerotic plaque, both
in humans and in mice (22, 107, 154). These phenotypes are
characterized by specific gene expression profiles and are
elicited by different stimuli, such as oxidative stress
FIG. 2. M1 and M2 markers. On specific stimulation, MF can assume different phenotypes and exert different func-
tions. The M1 and M2 phenotypes represent the two extremes of intermediate states displaying mixed functions and
markers. This graphical schematization depicts the principal markers, including membrane markers and released factors,
used to identify the polarization status of M1 and M2. Some markers expressed only by the M2b subtype are indicated in
brackets. M1MF produce pro-inflammatory cytokines and chemokines such as TNFa, IL-1, IL-18, IL-6, IL-12, IL-23, type I
IFNs (IFNa and IFNb), MCP1/CCL2, CXCL5, and CXCL8. The type II IFNc, produced by T lymphocytes and NK cells,
promotes, along with TLR ligands (or with CD40L expressed by T lymphocytes), a further M1 polarization via the IFNc
receptor. Cell surface molecules are expressed at high levels in M1, for example, CD80, CD86, MHC-II, TLR2, TLR4,
CD64, and CD40. M2MF produce IL-10, IL-1ra, growth factors such as IGF-1, PDGF, TGF-b, VEGF, FGF, and poly-
amines. M2-associated genes are Arg1, MRC1/CD206, IL-4R, RELMa/Fizz1/Retnla, and Chi3l3/YM-1. Cell surface
molecules over-expressed in M2 and used as M2-specific markers are Dectin-1, DC-SIGN, mannose, and galactose-type
receptors, for example, CD206, scavenger receptor A, scavenger receptor B1, CD163, MGL1-2/CLEC10A/CD301/Lectin,
MARCO, CXCR1, and CXCR. Several other molecules have been proposed as MF markers, including CD200R,
transglutaminase-2, and CD23, as reviewed by Roszer (287). Chi3l3, chitinase 3-like 3; CXCL, CXC chemokine ligand;
DC-SIGN, dendritic cell-specific ICAM-grabbing nonintegrin; FGF, fibroblast growth factor; IGF-1, insulin-like growth
factor-1; MARCO, MF receptor with collagenous structure; MGL1-2/CLEC10A, MP galactose-type calcium-type lectin/
C-type lectin domain family10, member A; MHC-II, major histocompatibility complex II; MRC1, mannose receptor C type 1;
PDGF, platelet-derived growth factor; RELMa/Fizz1, resistin-like molecule a/found in inflammatory zone 1; TGF-b,
transforming growth factor-b; TNFa, tumor necrosis factor-a; VEGF, vascular endothelial growth factor.
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(oxidized phospholipids) for Mox, hemoglobin–haptoglobin
complexes for M(Hb), heme for Mhem, and CXC chemokine
ligand (CXCL)4 for M4. Mox MF are believed to have a
particular ability to deal with oxidative stress, as they express
an increased glutathione/oxidized glutathione (GSH/GSSG)
ratio (154) and the generation of the Mox phenotype is me-
diated by nuclear factor (erythroid-derived 2)-like 2 (Nrf2).
The various origins of MF (from circulating monocytes or
from yolk sac), their polarization to pro-inflammatory or anti-
inflammatory subsets, and their heterogeneity have been de-
scribed. The nomenclature M1 and M2 emulates the T cells
Th1/Th2 classification and underlines the functional cross-talk
between lymphocytes and MF: Th1 lymphocytes produce
INFc, required for M1 polarization, and Th2 secrete IL-4 and
IL-13, which drive M2 polarization. Notably, this classification
is simplistic, due to the occurrence of several MF intermediate
polarization statuses (234). The obstacles and lack of consensus
in defining MF activation are described by the guidelines of
Murray and coauthors (234). Based on such guidelines, de-
scribing MF-activation in vivo requires an explicit description
of the populations under investigation, how they were isolated,
from which tissue and conditions, and which marker combi-
nations were used to ascertain MF activation.
III. Transcriptional Regulation of Polarization
A number of transcriptional factors participate in the dif-
ferential activation of MF. In this section, we describe the
most relevant, including the signal transducers and activators
of transcription (STATs), the IFN-regulatory factors (IRFs),
the nuclear factor jB (NF-jB), the hypoxia-inducible fac-
tors (HIFs), Kru¨ppel-like factors (KLF), the peroxisome
proliferator-activated receptors (PPARs), and several mi-
croRNAs (miRNAs) (170, 315).
The members of the STAT family involved in MF polar-
ization are STAT1, STAT2, STAT3, and STAT6. During M1
polarization, IFNc binds to its receptor and triggers Janus
kinase 1/2 ( JAK1 and JAK2)-mediated phosphorylation of
STAT1, which dimerizes and binds to the promoter region of
target genes, including iNOS and IL-12 (Fig. 3) (66). STAT1
and STAT2 are also involved in the autocrine response to
IFNb, released by LPS-activated MF; IFNb triggers the
formation of the STAT1–STAT2 heterodimers that bind to
IRF9 (Fig. 3) (see below within this same paragraph). In
STAT1-knockout (KO) mice, MF fail to produce TNFa and
NO, thus demonstrating that STAT1 is required for M1 po-
larization (179).
FIG. 3. Main pathways in M1. The main regulatory pathways in M1 polarization are represented here. M1 polarization is
fostered by pro-inflammatory stimuli such as LPS and IFNs. LPS binds to TLR4, which, through MyD88-dependent and
MyD88-independent (TRIF-dependent) pathways, induces the activation of IKK. IKK, in turn, phosphorylates IkB, which is
degraded, thereby releasing NF-jB. NF-jB migrates to the nucleus and drives the transcription of several genes that have
the NF-jB binding sites in their promoter region, for example, iNOS, MCP1, COX-2, and RANTES. IFNb binds to the
IFNa/b receptor that activates JAK3. JAK3 phosphorylates STAT1 and STAT2 that bind IRF9 to form the ISGF-3, which
drives the transcription of iNOS. IFNc binds to IFNc receptors, thus activating JAK1/2 that phosphorylate STAT1. pSTAT1
forms a homodimer that binds to DNA to induce the transcription of iNOS and IL-12. Some miRNAs are crucial for M1
polarization (e.g., miR-33, miR-127, miR-27a, miR-23a, and miR 24-2). COX-2, cyclooxygenase-2; IFNs, interferons;
IFNb, interferon-b; IKK, IkB kinase; iNOS, inducible NO synthase; IRF9, IFN-regulatory factor 9; ISGF-3, interferon-
stimulated gene factor-3; JAK3, Janus kinase 3; LPS, lipopolysaccharide; MCP1, monocyte chemoattractant protein 1;
miRNAs, microRNAs; MyD88, myeloid differentiation primary response gene 88; NF-jB, nuclear factor jB; NO, nitric
oxide; RANTES, regulated on activation, normal T cell expressed and secreted; STATs, signal transducers and activators of
transcription; TLR4, Toll-like receptor 4; TRIF, TIR-domain-containing adapter-inducing interferon-b.
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Conversely, STAT2 deficiency in mice does not block M1
polarization completely, but it impairs autocrine response to
type I IFNs (309). STAT3 is considered one of the key sig-
naling molecules in the induction of the M2 phenotype;
STAT3 is activated by IL-10 and, in turn, enhances IL-10
expression while inhibiting TNFa, IL-1b, and IL-12 pro-
duction. Notably, STAT3 activation by IL-6—considered a
prototypic inflammatory cytokine—in a pro-M2 mileu (i.e.,
in the presence of IL-4/IL-13) enhancesM2 polarization (90).
Stimulation of MF by IL-4/IL-13, both binding the IL-4
receptor-a (IL-4Ra) and activating either JAKe1/JAK3 (by
IL-4) or JAK1/Tyk2 (by IL-13), induces the phosphorylation
and activation of STAT6, which dimerizes and induces the
expression of most M2 genes, for example, Arg1, CD206,
resistin-like molecule alpha (RELMa)/Fizz1/Retnla, and
Ym1 (Fig. 4).
IRFs are also implicated in MF polarization. IRF1 (in-
duced by type I IFNs) and IRF5 (induced by TLR) are required
for proper M1 polarization and secretion of pro-inflammatory
cytokines (327, 384); indeed, IRF5 polymorphisms are asso-
ciated with immune-mediated diseases (115). IRF3 and IRF7
are activated in M1 and trigger type I IFNs production. IRF9
binds to the STAT1/STAT2 heterodimer to form the IFN-
stimulated genes (ISG) factor 3, which stimulates the tran-
scription of severalM1-related genes such as iNOS (Fig. 3). On
the other hand, IRF4 is specifically associated with M2 acti-
vation, as it is induced by IL-4-mediated activation of STAT6.
LPS binding to TLR4 and CD14 during M1 polarization
fosters NF-jB activation, through myeloid differentiation
primary response gene 88 (MyD88)-dependent and MyD88-
independent but TIR-domain-containing adapter-inducing
interferon-b (TRIF)-dependent pathways. NF-jB is normally
present—but kept inactive by IkB—in the MF cytoplasm.
TLR4 stimulation activates IkB kinase, which phosphory-
lates IkB and targets it for degradation; NF-jB is, therefore,
released and migrates to the nucleus, where it contributes to
its own activation by upregulating IL-1b and TNFa, these, in
turn, stimulating NF-jB activation.
Other genes with NF-jB-binding sites in their promot-
ers are iNOS, monocyte chemoattractant protein 1 (MCP1)/
CCL2, cyclooxygenase-2 (COX-2), and regulated on activa-
tion, normal T cell expressed and secreted (RANTES)-CCL5,
all related to M1 polarization. However, also M2 activation is
partly regulated by NF-jB; in fact, KO mice for the NF-jB
repressor, p50-NF-jB, display not only an exacerbated M1
response but also an impaired ability to establish a proper M2
response during parasitic infections (276). Also, the tran-
scription factor activator protein 1 (AP1) is activated by TLRs.
A condition of hypoxia, occurring in damaged tissues
and in case of bacterial infection—also due to high oxygen
FIG. 4. Main pathways in M2. The main regulatory pathways in M2 polarization are represented here. M2 polarization is
induced by pro-tolerogenic cytokines, namely IL-4, -13, and -10 that activate the JAK/STAT pathway. IL-4 and IL-13 act
through the same receptor, the IL-4Ra. The engagement of the receptor leads to the formation of JAK1/JAK3 or JAK1/Tyk2
dimers (when stimulated by IL-4 or by IL-13, respectively), fostering the phosphorylation of STAT6. pSTAT6 binds to
DNA and induces the transcription of the mannose receptor (CD206), Arg1, Fizz1, and Ym1 genes. Phosphorylation of
STAT3 and STAT6 induces the expression of M2-specific genes. IL-10 binds to the IL-10R1/2, a transmembrane receptor
complex consisting of two different chains, IL-10R1 and IL-10R2. The signal is transduced through the activation of JAK1,
which phosphorylates STAT3. pSTAT3 drives the transcription of Arg1 and of IL-10, thus creating an amplification
loop. Some miRNAs, including miR-223, miR-24, miR-125a-5p, miR-16, miR-155, and miRNA let-7c, suppress the pro-
inflammatory response, favoring an M2 phenotype. Arg1, arginase-1; IL, interleukin; IL-4Ra, IL-4 receptor-a; IL-10R1/2,
IL-10 receptor 1/2.
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consumption by inflammatory cells—can influence MF po-
larization. The effect of low oxygen partial pressure (pO2) on
cells is mediated by HIFs, two of which (HIF-1a and HIF-2a)
are also expressed byMF (57, 64). Low pO2 reduces the prolyl
hydroxylases (PHDs)-dependent degradation of HIF-1a and
HIF-2a, which can dimerize with HIF-1b and become active
gene regulators. HIF-1a and HIF-2a isoforms are directly in-
volved inM1 andM2 polarization, due to their influence, in an
antagonistic manner, on NO metabolism inducing the ex-
pression of iNOS and Arg1, respectively, although Arg1 seems
to be a target of both HIF isoforms (28, 328).
HIF-1a plays a crucial role in orchestrating part of the M1
polarization, since it downregulates CD206, enhances IL-1b
and the expression of other pro-inflammatory genes (324),
and stimulates glycolysis as well as pyruvate dehydrogenase
kinase-1 (PDK1) and glucose transporter type-4 (GLUT4)
expression to allow ATP production in hypoxia; indeed,HIF-
1a-KO (but not HIF-2a-KO) mice show alternative MF po-
larization and wound-healing improvement. In M1, HIF-1
and NF-jB are activated in parallel by hypoxia and ROS and
act synergistically to induce common target genes such as
iNOS; however, in some conditions, NF-jB seems to repress
HIF-1 target genes, causing alternative polarization under
hypoxia.
On the other hand, since NADPH-oxidases (NOX) and
iNOS use oxygen to produce ROS or NO, a low pO2 might
reduce their activity andM1 pro-inflammatory function. HIF-
2a is barely detectable in M1, whereas it is upregulated in M2
where HIF-1a is downregulated. However, a decrease of the
pro-inflammatory response has also been detected inHIF-2a-
KO mice [for references see Bru¨ne et al. (28)]. Besides Arg1,
HIF-2 triggers anti-oxidant protein expression and ECM
production. In M2, both HIF isoforms promote vascular en-
dothelial growth factor (VEGF) signaling and angiogenesis,
which are crucial for the regenerative process.
Interestingly, it has been found that PHD2 downregulation
is critical for alternative polarization and promotes capillar-
ization and arteriogenesis independently of hypoxia through
the NF-jB pathway (120); activation of the angiopoietin
receptor TIE2 in ischemia-associated MF, triggered by en-
dothelium shear stress-released VEGF, induces PHD2
downregulation in normoxia, which activates the canoni-
cal NF-jB pathway, further upregulating the pro-
arteriogenic TIE2. This is associated to M2 polarization and
enhanced capillarization; indeed, arteriogenesis occurs in
sites distant from the hypoxic area (120). It has more recently
been observed that, in human MF under hypoxic conditions, a
transcriptomic switch triggered by both HIF-1a and HIF-2a
together (not by HIF-1a alone) occurs; this switch upregulates
glycolytic enzymes, increasing anaerobic glycolysis (143).
HIF isoforms are differentially activated, HIF-1a being
induced by Th1 cytokines and HIF-2a by Th2 cytokines
(e.g., IL-4). HIF-1a clearly accumulates in M1 in normoxia
conditions as well, paired with the contribution of NF-jB
binding to its promoter. HIFs are also redox-sensitive tran-
scription factors, since PHD is influenced not only by oxygen
but also by NO and ROS. M1-produced ROS reduce PHD
activity and promote HIF-1a expression also under an ambient
oxygen level. Also, NO represses PHD and stabilizes HIF-1,
which, in turn, induces iNOS in a positive feedback typical of
M1 (see sections IV.C.1, IV.A.3.2, and V). However, NO
becomes destabilizing under hypoxic conditions; by competing
with oxygen for the binding to cytochrome c oxidase (COX),
NO might leave more oxygen available for PHD activity (28).
Finally, LPS-induced TLR4 signaling triggers a cross-talk
between HIF-1a and apoptosis signal-regulating kinase-1
(ASK1) pathways, both activated by ROS. ASK1 contributes
to HIF-1a stabilization likely via p38 mitogen-activated
protein kinase (MAPK), which is typically involved in M1
polarization (164, 322, 334). Even though HIF-1a levels
mostly depend on PHD, also nuclear factor of activated T
cells (NFAT) and STAT3—crucial for the M2 phenotype—
seem to be required for HIF-1a expression as well as for the
angiogenic role of MF; whereas transcriptional regulation of
HIF-2a is barely known [for references see Bru¨ne et al. (28)].
Through HIF-1a, hypoxia also upregulates some DAMP re-
ceptors such as RAGE and P2X7R, thus influencing MF
polarization (325). HIFs promote stemness as well, including
that of human embryonic stem cells, thus increasing their
regenerative potential. Stem cells reside within hypoxic re-
gions and HIFs are involved in their homeostasis also by
decreasing their reliance on oxidative metabolism. HIFs
maintain stemness also in cancer stem cells (203).
KLFs are zinc-finger transcriptional factors. Several mem-
bers of the KLF family are involved in the MF-polarization
process. KLF2, KLF10, and KLF13 attenuate M1 polariza-
tion through different pathways: (i) KLF2 inhibits NF-jB-
mediated response to pro-inflammatory cytokines; (ii) KLF10
binds the promoter of TGF-bRII (257); and (iii) KLF13 me-
diates the anti-inflammatory effect of miR-125a-5p (11). On
the other hand, KLF6 enhances the expression of pro-
inflammatory genes in MF (159). As for KLF4, its function is
controversial; it is upregulated in LPS/IFNc-stimulated murine
J774MF, where it cooperates with NF-jB to enhance iNOS
expression (89); whereas by contrast, it is over-expressed in
murine peritoneal M2 and adipose tissue M2MF from obese
humans, where it interacts with STAT6 and inhibits NF-jB-
mediated M1 response (182).
PPARc is known to induce M2 activation; in fact, ad-
ministration of rosiglitazone, a PPARc agonist, leads to an
increased expression of Arg1, found in inflammatory zone 1
(Fizz1), and IL-10 (127). On exposure to Th2 stimuli medi-
ating M2 polarization, PPARc deficiency downregulates
Arg1 and IL-10 likely through the induction of miR-223
(392). Inhibition of pro-inflammatory cytokine signaling, for
example, by suppressor of cytokine signaling (SOCS) pro-
teins, also occurs in M2.
Several miRNAs have emerged as crucial players in MF
polarization (Figs. 3 and 4) (148, 243, 253, 330, 391, 392).
Along with miRNAs, other epigenetic mechanisms modu-
late MP polarization; just to give some examples of an ex-
tremely wide field, methylation of lysine 4 of histone 3
(H3K4) seems to be involved in TNFa transcriptional reg-
ulation (181). On the other hand, Xia et al. reported that
methylation of H3K4 leads to TNFa and IL-6 down-
regulation in a murine model of sepsis (383). Moreover, the
histone demethylase Jumonji domain-containing 3 seems to
not only contribute to a fine regulation of LPS-dependent
M1 gene expression (68) but also be crucial for M2 polar-
ization (303). Further, histone acetylation represents an-
other mechanism of transcriptional control; for example,
histone deacetylases 3 (HDAC3) removes the acetylation on
the enhancers of IL-4-induced genes, thus representing a
brake for M2 polarization (148, 230).
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IV. Metabolic Features of M1 and M2
In addition to the earlier described features characterizing
M1 and M2, these two subsets might also be distinguished by
key metabolic differences. Several years ago, Newsholme
and collaborators proposed that MF polarization in mice is
associated to a metabolic reprogramming; in synthesis, the
switch toward a glycolytic or an oxidative metabolism is
required for M1 andM2 polarization, respectively. Quiescent
MF rely mostly on mitochondrial oxidative respiration to
produce ATP, whereas M1 obtain energy mainly by glycol-
ysis and M2 by enhanced oxidative metabolism (Fig. 5)
(241, 242).
Importantly, the metabolic status characterizing differen-
tially activated MF also affects their inflammatory state;
therefore, different metabolic pathways not only are a dif-
ferent way to produce energy but also confer peculiar phe-
notypes and functions to MF subsets. Although a growing
body of evidence emphasizes the crucial role of metabolic
reprogramming in MF activation, the signaling allowing the
metabolic switch leading to M1 or M2 activation is currently
largely unknown.
A. M1-polarized MF
1. Enhanced glycolysis and reduced oxidative phosphor-
ylation. M1 activation is associated with an oxidative
phosphorylation (OxPhos) to glycolysis switch (Fig. 5). The
first evidence of a higher glucose consumption in murine MF
on pathogen stimulation was obtained in 1970 (124). This
was confirmed in several manuscripts describing that, in LPS/
IFNc–polarized MF, an enhanced glycolysis fosters in-
creased glucose uptake and conversion of pyruvate to lactate,
the latter found in high concentrations both intra- and ex-
tracellularly; glucose is fermented to lactate, even though
oxygen is sufficient to support OxPhos (241, 251).Vice versa,
glucose metabolism remains unaltered in IL-4/IL-13-
stimulated MF and dendritic cells (87, 164, 285, 355). In line
with this, although not fully elucidated, endogenous GLUT4
seems to be crucial for M1 activation (238, 251).
In addition, metabolomic screenings and cDNA microarray
gene expression analysis have shown that M1 upregulate gly-
colytic genes within 24h after LPS stimulation, whereas they
downregulate the mitochondrial ones. This is associated with a
reduction of the respiratory chain activity evaluated by oxygen
consumption rate (OCR), which is a measurement of cellular
oxidative metabolism. It is also associated with an increased
extracellular acidification rate, which is an indication of the
glycolytic rate (238); in fact, extracellular H+ excretion derives
both from anaerobic glycolysis-produced lactate (glucose is
converted to lactate- andH+; glycolytic acidification) and from
tricarboxylic acid (TCA) cycle-derived CO2 (exported CO2 is
hydrated to H2CO3, which then dissociates to HCO3
- and H+;
respiratory acidification).
Although the contribution of CO2 to extracellular acidifi-
cation is often considered negligible, the proportions of
glycolytic and respiratory acidification vary depending on the
experimental conditions (221). To sum up,M1 polarization is
characterized not only by enhanced glycolysis but also by
repression of mitochondrial OxPhos (263, 264). M1 polari-
zation also reduces the NAD+/NADH ratio in mice, this being
in line with reduced oxidative respiration and NADH oxi-
dation (Fig. 5) (214).
FIG. 5. Main metabolic features of M1- and M2-polarized MF. M1MF obtain energy mainly by glycolysis with
production and release of lactate, whereas M2 mostly rely on enhanced mitochondrial oxidative respiration based on both
glucose and FFA utilization; this causes a lower NAD+/NADH ratio in M1. In M2, the TCA cycle is regular, whereas M1
are charcterized by breakpoints in the TCA. In M1, the PPP is more active, along with a higher production of ROS,
compared with M2 subsets. Finally, M1 activate iNOS and produce high amounts of NO and citrulline, whereas M2 robustly
activate Arg1 ornithine and polyamines. The glutamate/glutamine metabolism plays a crucial role in supporting M2
polarization. FFA, free fatty acid; PPP, pentose phosphate pathway; ROS, reactive oxygen species; TCA, tricarboxylic acid.
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As recently reviewed by Van den Bossche et al. (355), gly-
colysis is also necessary for M1 activation given that it provides
signals driving this polarization route, with glycolytic enzymes
being crucial in supporting pro-inflammatory function. For ex-
ample, the glycolytic activator 6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase 3 (PFKFB3) enhances the ability of
murine MF to remove virus-infected cells (147). Moreover,
when glycolysis is limited, glyceraldeyhe phosphate dehydro-
genase (GAPDH) is not fully engaged in this cycle and might
inhibit TNFa and IFNc translation by binding their mRNA.
Therefore, glycolysis is a metabolically regulated signal-
ing mechanism that is required to control cytokine production
(38, 211). Moreover, a-enolase is expressed on the humanM1
surface where it stimulates the production of pro-inflammatory
cytokines (9), and pyruvate kinaseM2 (PKM2) acts directly on
HIF-1a and upregulates IL-1b. Further, through the activation
of the eukaryotic translation initiation factor 2 alpha kinase 2—
which modulates the inflammasome—PKM2 also indirectly
promotes pro-IL-1b activation in mice (256). Finally, it has
also been suggested that in coronary artery disease patients,
over-utilization of glucose drives ROS production, leading to
PKM2 nuclear translocation where it phosphorylates and ac-
tivates STAT3 to boost the expression of IL-1b and IL-6 (310).
Glycolysis is required to induce and sustain a pro-
inflammatory status also in other immune cells such as den-
dritic ones (86, 206, 263, 264). In fact, glycolysis produces
low amounts of energy compared with OxPhos (2 ATP/
glucose vs. around 30 ATP/glucose). However, it can be
quickly activated, provides rapid energy, and reduces pro-
duction of intermediates. As such, it has been suggested as
crucial for acute bacterial killing in highly proliferating
bacterial infection (164, 332).
2. Pentose phosphate pathway. Classical M1 activation
also enhances the pentose phosphate pathway (PPP), branch-
ing from glycolysis and essential for NADPH production used
to produce both ROS (by NOX) and NO (Fig. 6). Through the
PPP, erythrose (precursor of amino acids) and ribose (nucle-
otide synthesis intermediate) are also synthetized by glucose
(236, 355).
3. Breakpoints in the TCA cycle and TCA intermediates
accumulation. Another typical consequence of the meta-
bolic reprogramming characterizing M1 polarization is a flux
discontinuity at several levels of the Krebs cycle, as dem-
onstrated in murine MF (Figs. 6 and 7) (145). Such inter-
ruptions lead to the accumulation or reduction of some TCA
intermediates, which influence the inflammatory response.
However, the results of these studies are controversial due to
the quick changes in metabolism and to the anaplerotic re-
actions feeding the TCA cycle. Notably, the TCA cycle
fueled by both pyruvate and glutamine is globally maintained
on LPS stimulation, whereas OxPhos decreases and NADH
excess might possibly be converted into NADPH to support
NOX activity during phagocytosis, as found in murine MF
cell lines (207).
a. Citrate/isocitrate level
(1) A robust increase of citrate occurs in M1 (Fig. 7).
Citrate might translocate from the mitochondria to the
cytosol by the citrate carrier (CIC; which is upregu-
lated in M1) and be transformed into oxalacetate and
acetyl coenzyme A (acetyl-CoA) by the ATP-citrate
lyase (Fig. 7). Flux discontinuity at the citrate level
might be responsible for the increased synthesis of
acetyl-CoA, allowing higher synthesis of fatty acids
(FA) and prostaglandins, characterizing the M1 subset.
FA are necessary for M1 to reorganize the plasma
membrane and rapidly produce organelles that are
crucial for cytokine synthesis and secretion, as
FIG. 6. Glycolysis, PPP
and NO production in M1
subsets. Glycolysis in M1 is
the main route of ATP and
NADH production; based on
this, lactate is over-produced
both intra- and extracellu-
larly. The PPP, branching
from glycolysis, is also up-
regulated in M1. PPP is cru-
cial for NADPH production,
which is necessary for ROS
production by NADPH-
oxidase. Moreover, NADPH
is used, together with argi-
nine and O2, to produce NO
by iNOS activation. NO and
itaconate have been sug-
gested to reduce the oxida-
tive respiration by inhibiting
COX and SDH. Moreover,
also erythrose and ribose are
synthetized by glucose
through the PPP. COX, cy-
tochrome c oxidase; SDH,
succinate dehydrogenase.
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demonstrated both in vivo and in vitro (86, 87, 208,
355, 378). FA synthesis occurring in M1 demon-
strates that glycolysis is boosted and oxygen con-
sumption is decreased yet not abrogated, as observed
in vitro (214). Citrate is also critical for the produc-
tion of pro-inflammatory mediators such as NO
(140); if CIC or ATP-citrate lyase are inhibited, NO
and ROS production by M1 is blocked (140, 141).
(2) Deriving from the TCA cycle intermediate cis-
aconitate (which, in turn, derives from the accumulated
citrate), the itaconic acid is also highly concentrated
in murine M1 (Fig. 7) (320). Pyruvate dehydrogenase
(PDH) is necessary to obtain citrate (and, in turn,
itaconate) from pyruvate (355). Itaconic acid acts as a
microbicidal agent disrupting the glyoxylate cycle
used by some pathogens (e.g., Salmonella en-
terica), but not by mammalian cells (209). Itaconic
acid is secreted on M1 activation. In addition,
Michelucci et al. have found that silencing the im-
munoresponsive gene 1 (Irg1)—the enzyme cata-
lyzing the decarboxylation of cis-aconitate to
itaconate—reduces MF antimicrobial activity (209,
331). Indeed, Irg1 is robustly upregulated in M1,
thus linking the accumulation of citrate and succi-
nate (Fig. 7) (61, 168).
(3) More recently, disclosure of the metabolic rewiring
typical of the M1- and M2-polarized states obtained
by high-throughput metabolic and transcriptional data
profiling (CoMBI-T analysis), besides confirming
previous findings, has highlighted that M1 polariza-
tion is characterized by TCA cycle breakpoint at the
isocitrate dehydrogenase 1 (Idh1) level (Fig. 7); M1
display higher levels of isocitrate compared with
M0MF and this was likely due to transcriptional
downregulation of Idh1, the enzyme catalyzing the
isocitrate to a-ketoglutarate reaction.
b. Succinate level
(1) Another TCA flux discontinuity occurs at the succi-
nate dehydrogenase (SDH) level; the succinate-to-
fumarate transition is impaired, and the steady-state
concentration of succinate and malate increases in M1.
Data suggest that malate accumulates because it de-
FIG. 7. Breakpoints in the TCA cycle in M1. Some breakpoints in the TCA cycle characterize the M1 subsets. Citrate
levels increase in M1MF; citrate can translocate to the cytosol by means of the CIC and be metabolized by the ATP citrate
lyase in oxalacetate and acetyl-CoA. Increased levels of acetyl-CoA might be used for FAS as well as for prostaglandin
synthesis, both increasing in M1. Citrate is also used for the production of NO. The microbial agent itaconate has also been
found at a high concentration in M1. Itaconate is formed by decarboxylation of cis-aconitate that is mediated by the enzyme
Irg1, which is upregulated in M1. Another breakpoint within the TCA cycle flow occurs at the Idh1 level, the enzyme
catalyzing the reaction from isocitrate to a-ketoglutarate. Due to Idh1 downregulation, high levels of isocitrate are found in
M1. Another flux discontinuity in the TCA cycle occurs at the SDH level, leading to a high concentration of succinate,
which is able to inhibit PHDs and, as a consequence, HIF-1a is not degraded and drives the transcription of glycolitic genes
as well as of the inflammatory cytokine IL-1b. Therefore, succinate has been considered an inflammatory signal that might
also be released and act on other cells via the G-coupled SUCNR1, thus increasing HIF-1a-dependent IL-1b expression.
acetyl-CoA, acetyl coenzyme A; CIC, citrate carrier; FAS, fatty acid synthesis; HIF, hypoxia inducible factor; Idh1,
isocitrate dehydrogenase 1; Irg1, immunoresponsive gene 1; PHDs, prolyl hydroxylases; SUCNR1, succinate receptor 1.
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rives from the aspartate-arginosuccinate cycle, an
anaplerotic set of reactions connecting the urea cycle
(arginine-ornithine-citruline conversion) and NO pro-
duction with the Krebs cycle (Fig. 8) (145). This was
confirmed by inhibition of glutamic oxaloacetic
transaminase 2-mediated aspartate production, which
reduced NO production and iNOS expression, in turn
decreasing IL-6 and blocking M1 conversion.
Based on these data, NO seems to be largely pro-
duced through the aspartate-arginosuccinate shunt.
As shown in cultured murine dendritic cells, NO
contributes to suppressing mitochondrial respiration
by competing with oxygen and inhibiting SDH (87).
To summarize, it seems that in M1, the aspartate-
arginosuccinate shunt allows TCA cycle anaplerosis,
which is useful in the context of the breakpoint at the
SDH level. This shunt coordinates the NO cycle with
TCA cycle anaplerosis (Fig. 8) (145).
(2) Further, accumulated succinate, similar to NO, in-
hibits PHDs (Fig. 7). Usually, in the presence of
oxygen, the a-ketoglutarate-dependent dioxygenases
PHDs hydroxylate HIFs, targeting them for protea-
somal degradation. At low pO2, PHDs are inhibited;
HIF-1a is not degraded, thus stimulating glucose up-
take, glycolytic genes, and IL-1b transcription while
inhibiting pyruvate oxidation and favoring lactate re-
duction. PHDs inhibition by succinate stabilizes HIF-
1a also in the presence of oxygen (334); succinate is,
therefore, considered an inflammatory signal since
HIF-1a plays a crucial role in orchestrating part of the
M1 polarization by promoting glycolysis, GLUT4 and
IL-1b expression, and MF migration.
Glycolysis is crucial for MF migration, whose
inhibition suppresses systemic inflammation in vivo
(308). Notably, in LPS-treated MF, inhibiting gly-
colysis by 2-deoxy-d-glucose (2DG) reduces IL-1b
(most likely due to succinate accumulation) but not
TNFa expression, thereby demonstrating the specific-
ity of the effect of succinate on IL-1b (214, 238, 334).
(3) Succinate might also be released by M1, acting ex-
tracellularly via the succinate receptor 1/G-protein
coupled receptor-91 (SUCNR1/GPR91) expressed in
many tissues. Recycling succinate induces a feed-
forward loop of pro-inflammatory MF activation,
which increases HIF-1a-dependent IL-1b expression.
In fact, SUCNR1 synergizes with TLR on both hu-
man and murine dendritic cells to enhance the func-
tions associated with antigen presentation (Fig. 7)
(185, 290). Moreover, an LPS-dependent succinyla-
tion of numerous proteins—whose consequences are
unknown—has been reported (335).
(4) An increased succinate oxidation via SDH on M1
polarization, as observed in murine BMDM, has also
been proposed (214). In addition to HIF-1a stabilization,
succinate might have another inflammatory critical
role; M1 polarization seems to drive mitochondrial
membrane hyperpolarization (glycolysis supporting
ATP generation), which, paired with SDH-mediated
succinate oxidation to fumarate, leads to ROS generation
(and, in turn, to IL-1b expression) via reverse electron
transport through complex I rather than activating the
conventional electron transport (214, 251, 317).
This hypothesis suggests a repurposing of mito-
chondria fromATP synthesis to ROS production, which
promotes a pro-inflammatory state (214). This is ac-
companied by mitochondrial supercomplex destabi-
lization; complexes I, II, and IV can accumulate as
supercomplexes, improving coupling and reducing ROS
formation. However, complex I, and, as a consequence,
the whole supercomplex, is destabilized when MF are
FIG. 8. The aspartate-
arginosuccinate shunt al-
lows anaplerosis of the TCA
cycle in M1. Considering that
the succinate-to-fumarate
transition is impaired, the
concentration of succinate
and malate increases in M1. It
has been suggested that ma-
late accumulates because it
derives from the aspartate-
arginosuccinate cycle that
connects the urea cycle and
iNOS-dependent NO produc-
tion with the TCA cycle. NO
is largely produced through
the aspartate-arginosuccinate
shunt. NO inhibits the SDH
and reduces mitochondrial
respiration.
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activated by bacteria; this activates SDH, which seems
necessary for the control of bacteria (214), although the
role of SDH and its link with IL-1b production is far
from being clear. Succinate oxidation also leads to de-
creased anti-inflammatory gene expression; in line with
this, inhibiting succinate oxidation by dimethyl mal-
onate promotes an anti-inflammatory outcome.
To summarize, M1 polarization is characterized by en-
hanced glycolysis and PPP, whereas OxPhos decreases.
Glycolysis is additionally necessary for M1 activation by
providing signaling mediators driving it. Flux discontinuities
on several levels of the Krebs cycle are also features of
M1 polarization and lead to a robust increase of pro-
inflammatory succinate and citrate, Irg1, isocitrate, and mi-
crobicidal itaconic acid and to the downregulation of Idh1.
The variation of Irg1 and itaconate concentration represents a
strong marker of M1 polarization similar to iNOS activation
and NO over-production (see section IV.C). Specifically,
PFKFB3, PMK2, a-enolase, citrate, succinate, and itaconate
are not only consequences but also causal of M1 polarization.
B. M2-polarized MF
1. Enhanced OxPhos. Differently from M1, alterna-
tively activated murine M2 have an intact TCA cycle and an
efficient OxPhos supporting their energy demands and phe-
notype (Figs. 5 and 9) (357). Based on some authors’ find-
ings, glucose uptake also increases in M2 compared with
untreated MF but is lower than in M1, and it is mainly oxi-
dized by mitochondria; OxPhos accounts for higher but
slower ATP generation, which can be sustained for a longer
period compared with glycolysis (355). This is useful for the
resolution of inflammation and also against prolonged para-
site infections. OxPhos requirement for M2 polarization has
been revealed by oligomycin-mediated inhibition of ATP-
synthase and OCR, blocking IL-4-mediated M2 polarization.
Also, OxPhos inhibition by rotenone impairs M2 polarization
in murine BMDM (126).
2. Reduced PPP. Thecarbohydratekinase-like (CARKL)
protein is a repressor of M1 activation both in human and in
murine MF. In fact, CARKL phosphorylates the PPP inter-
mediate sedoheptulose in sedoheptulose-7-P, thus stimulating
the nonoxidative phase of this cycle; this reduces NADPH
production and counteracts ROS production typical of M1.
CARKL is critical for PPP regulation; its expression increases
in M2 whereas it decreases in M1 (Fig. 9) (126).
3. Free fatty acid b-oxidation and glycolysis requirement
in differentially polarized MF is controversial. The strict
requirement of free fatty acid (FFA) b-oxidation (FAO) for
M2 polarization has recently become a matter of debate (134,
237, 332, 355, 357). By using BMDM, Vats et al. suggested
that FAO is crucial for M2 polarization; based on their data,
FFA uptake, and FAO increase in M2 compared with un-
treated MF andM1; whereas IL-4-stimulated MF upregulate
FIG. 9. EnhancedOxPhos, upregulatedArg1, and reducedPPP inM2polarization. InM2, the glycolysis is still greatly used
by the cell, but pyruvate ismainlymetabolized inacetyl-CoA,which is alsoobtained fromFAOand feeds theTCA(Krebs) cycle and,
in turn, the respiratory chain. Another feature of anti-inflammatoryMPs is the upregulation of the enzyme Arg1, which is inducible
and competes with iNOS for their common substrate l-arginine to produce ornithine and urea, thus reducing the production of NO.
The CARKL phosphorylates the PPP intermediate sedoheptulose in sedoheptulose-7-P, stimulating the nonoxidative phase of this
cycle and reducing NADPH, ROS, and NO production typical of M1 activation. CARKL, carbohydrate kinase-like; FAO, FFA b-
oxidation; OxPhos, oxidative phosphorylation.
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acyl-CoA dehydrogenases and enoyl-CoA hydratases
involved in FAO (357). mRNAs of PPARc-coactivator-1b
(PGC-1b) and of genes involved in FFA uptake, transport, and
oxidation—for example, lipoprotein lipase, fatty acid trans-
porter (CD36/FAT), carnitine palmitoyltransferase 1 (CPT1),
medium chain acyl-CoA dehydrogenase, long chain acyl-
CoA dehydrogenase, and PPARc—are also upregulated in
M2 and downregulated in LPS/IFNc-polarized M1 (357).
Triglycerides lysosomal lipolysis, after CD36-mediated
lipoprotein uptake, fuels an intense OxPhos; lipolysis was
found to be essential to allow oxidative metabolism and M2
polarization, both in humans and in mice (134). In line with
this, and further corroborating the hypothesis of the key role
of FAO in M2 polarization, PPARc, necessary for mito-
chondrial function and FAO, enhances and is crucial for M2
activation and consequent reduction of inflammation; in fact,
its inhibition impairs alternative polarization (163, 249).
Consistently, M2 activation requires PGC-1b and the in-
duction of the transcription factor STAT6, enhancing mito-
chondrial respiration through the upregulation of PPARc but
also PGC-1a and PGC-1b, the master regulators of mito-
chondrial biogenesis (237). Accordingly, some authors have
found that oxidative metabolism increases on M2 polariza-
tion and etomoxir-mediated FAO inhibition, similar to the
inhibition of OxPhos by oligomycin or by the mitochondrial
uncoupler, carbonyl-cyanide-4-trifluoromethoxy-phenylhy-
drazone, which completely abolishes IL-4-induced polari-
zation as highlighted by the downregulation of the M2
polarization markers Arg1, Dectin-1, CD301, CD206, and
RELMa (134, 238).
More recently, however, the strict FAO requirement for
M2 polarization has become controversial (208); even though
FAO and oxygen consumption increase in human M2, the
global oxidative metabolism—not specifically FAO—might
be crucial for M2 polarization, since glucose can be used to
fuel OxPhos. In fact, although FAO decreases during M1
polarization, it has been demonstrated, in both murine and
human MF, that etomoxir-mediated FAO inhibition does not
block mitochondrial respiration and does not inhibit M2
polarization (237, 332, 355). Notably, suppression of glucose
oxidation (not FAO suppression) would inhibit M2 polari-
zation (332); this hypothesis is corroborated by the obser-
vation that 2DG-dependent glycolysis-inhibition—similar to
mitochondrial ATPsynthase inhibition by oligomycin—
blocks respiration and M2 polarization, as observed both in
human and in murine MF both in vivo and in vitro (63, 246,
353, 397).
Glucose might fuel the TCA cycle for mitochondrial res-
piration in M2 and, as a consequence, glycolysis might be
crucial not only for M1 but also for M2 polarization. In hu-
mans, FAO seems to be dispensable for M2 polarization; in-
deed, IL-4 leads to an unchanged expression of PGC-1a/b and
to moderate changes in mitochondrial oxidative metabolism
and FAO rate, thus highlighting a possible key difference be-
tween mice and humans (97, 332). Moreover, CPT2 knock-
down and FAO disruption allows M2 activation, again
demonstrating that FAO is dispensable for M2 activation
(244); accordingly, some manuscripts report that FAO inhi-
bition does not influence STAT6 phosphorylation and PGC-1b
expression that are necessary for M2 polarization (238, 357).
Notably, the effect of etomoxir-mediated FAO inhibition
is highly controversial not only because of differences among
mice and humans but also because, as discussed in Namga-
ladze and Bru¨ne (238), different concentrations of etomoxir
trigger different effects. Low concentrations of etomoxir in-
hibit 90% of FAO whereas respiration is only slightly af-
fected; this means that cells shift to another metabolism to
fuel OxPhos. High etomoxir concentrations block FAO and
also decrease respiration by 50%; they further reduce the
expression of IL-4-target genes also in CPT2-/- MF.
Moreover, genetic ablation of the FA transport protein 1
(FATP1) has been used to get insights into the role of FAO,
without clarifying the issue. In fact, FATP1 deletion in mu-
rine MF triggers an FAO-to-glycolysis switch with iNOS
upregulation and Arg1 downregulation, without altering the
expression of M1 surface markers, including CD80, CD86,
and major histocompatibility complex II, MHC-II (151). Also,
the role of the adipocyte triglyceride lipase fueling FAO inMF
is controversial (238).
Interestingly, it has also been proposed that IL-4 acts by
activating AKT and, in turn, mammalian target of rapamycin
(mTOR) complex-1 (TORC1), which stimulates glucose
metabolism (63). Other authors reported that IL-4, in asso-
ciation with M-CSF, also acts through mTORC2 and IRF4 to
increase glucose metabolism in murine MF, both in vitro and
in vivo (135). This pathway resulted critical for alternative
MF activation; in fact, deletion of Rictor (a component of
mTORC2) reduces glycolysis and M2 activation. In conclu-
sion, the necessity for glycolysis might not be typical of M1,
but, vice versa, might be crucial for both inflammatory and
anti-inflammatory responses. mTOR signaling regulation of
MF polarization suggests that prolonged starvation might
lead to an interesting interplay between mTOR signal-
ing, metabolism, and MF polarization, which needs to be
explored (30).
4. Glutamine-relatedmetabolism. Recently, the glutamine/
glutamate-relatedmetabolismand theUDP-N-acetylglucosamine
(UDP-GlcNAc) biosynthesis, through the hexosamine bio-
synthetic route, have been found to be enhanced and critical for
M2 polarization in murine BMDM in vitro (145). Also, high
levels of UDP-glucose and UDP-glucoronate characterize this
polarization status (Fig. 10). Several studies confirm the crucial
role of glutamine in the TCAcycle forM2 activation (124, 242,
285). The importance of glutamine-dependent pathwaysmight
also be associated with the requirement of UDP-GlcNAc as a
sugar donor for N-glycosylation, possibly to properly fold and
export cell surface or secretion proteins (145).N-glycosylation
is crucial for M2 activation, since highly glycosylated lectin/
mannose receptors are the most typical markers for M2 po-
larization; the N-glycosylation inhibitor tunicamycin inhibits
the expression of the M2 markers RELMa, CD206, and
CD301.
Moreover, UDP-GlcNAc might be used as a sugar donor
for O-glycosylation, another pathway connecting cellular
metabolism with signaling (145, 379). Finally, glutamate/
glutamine support an active TCA (Fig. 10). In general, the
availability of amino acids and nutrients in the microenvi-
ronment has a profound impact on metabolism and, by ex-
tension, on function. Metabolic intermediates are not just a
source of energy, but they can also be directly implicated in
the definition of a particular MF phenotype (117). For ex-
ample, in lymphocytes, the inability to transport some amino
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acids (including glutamine) leads to inflammation (251). An
extensive literature on the impact of amino acid deficiency on
immune cells has been recently reviewed (192, 233).
In synthesis, M2 are characterized by an intact TCA cycle
and a high and efficient OxPhos, which is required for M2
polarization; whereas PPP decreases and CARKL, a repres-
sor of M1 activation, is upregulated. Glutamine is also crucial
for M2 activation; moreover, PPARc fosters M2 polarization,
and GAPDH inhibits inflammation. Notably, the key role of
FAO in M2 activation has recently been questioned, since it
has been proposed that the global oxidative metabolism, also
fueled by glycolysis, but not specifically FAO, is crucial for
M2 polarization.
C. NO and ROS in M1- and M2-polarized MF
1. NO/iNOS and ROS in M1. Oxidative stress is asso-
ciated to inflammation; classically activated M1 recognize
invading microbes or cancer cells, engulf them into phago-
somes, and destroy them on phagosomes-lysosomes fusion.
M1 bactericidal action mainly relies on ROS production
occurring in phagolysosomes, and on the production of the
cytosolic diffusible NO, which reacts with phagolysosomal
ROS to produce highly toxic species. NO and ROS account
not only for M1 toxic, antimicrobial, and antitumor effects
but also for the redox signaling that modulates many tran-
scriptional events; this mainly occurs at low intracellular free
radical levels, when changes elicited by ROS and NO are
subtle and reversible.
Vice versa, high NO and ROS levels induce oxidative
stress, which is a disturbance of the pro-oxidant/antioxidant
balance occurring when the redox state redox systems shifts
to the oxidized state. If prolonged, this condition is toxic and
bactericidal and leads to protein, DNA, and lipid oxidation
and damage. NO and ROS toxicity depends not only on their
concentration but also on the type of oxidative species pro-
duced (see the subsequent paragraphs within this section).
A key effector molecule preferentially expressed in in-
flammatory M1 is the cytokine-inducible iNOS (NOS2); it
produces NO from l-arginine, thus accounting for a pro-
longed period of NO production, which, therefore, reaches a
high concentration and elicits bactericidal and tumoricidal
effects (Fig. 6) (130, 231, 234). iNOS requires l-arginine,
NADPH, and molecular oxygen to generate NO and
FIG. 10. The glutamine/glutamate-related metabolism and the UDP-GlcNAc biosynthesis are critical for M2 po-
larization. Glutamine plays a key role in the activation of the M2-polarization program. UDP-GlcNAc is necessary as a
sugar donor for N-glycosylation and O-glycosylation. UDP-GlcNAc originates through the contribution of glutamine and
glutamate through the hexosamin pathway; from glucose-6-P, fructose-6-P is formed and by addition of glutamine, is
transformed into glucosamine-6-phosphate, undergoing an addition of acetyl-CoA to produce N-acetyl-glucosamine-6-
phosphate. With the contribution of ribose (obtained by the PPP), aspartate (obtained by a reaction involving glutamate),
carbamoyl phosphate, and through the route of the pyrimidine biosynthesis, UDP-GlcNAc is formed. High levels of UDP-
glucose and UDP-glucoronate characterize the M2 polarization status as well. Glutamate/glutamine support an active TCA,
by, for example, producing a-ketoglutarate. UDP-GlcNAc, UDP-N-acetylglucosamine.
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citrulline. NO might also be produced in the absence of ox-
ygen (likely in mitochondria) from nitrite reduction caused
by some heme proteins (28, 106, 131). Two other NOS iso-
forms exist: endothelial NO synthase (eNOS/NOS3) and
neuronal NO synthase (nNOS/NOS1), constitutively ex-
pressed and releasing continuous but low amounts of NO.
Moreover, a mitochondrial NO synthase (mt-NOS) has
been hypothesized; although it awaits characterization, it has
been proposed that mt-NOSmight directly interact with COX
to block its activity in hypoxic conditions (104, 271). No-
tably, although production of NO by NOS is considered a
coupled reaction, NOS might also produce ROS by un-
coupled reactions, although their exact stoichiometry awaits
further clarification (98, 302).
The NO moiety is added to thiols, secondary amines, or
hydroxyl groups of cellular macromolecules by nitrosative
reactions. In particular, S-nitrosylation mostly occurs at low
NO concentrations and is the reversible addition of an NO
moiety to sulfhydryl residues, generating S-nitrosothiol de-
rivatives characterized mostly by regulative roles (220). NO
binds heme and nonheme iron targets (Fe-nitrosylation) and
inhibits the electron transport chain (ETC) both reversibly, by
competing with oxygen for the COX heme, and irreversibly,
by reacting (mostly as peroxynitrite) with iron-sulfur clusters
in complexes I and II (229). In highly inflammatory condi-
tions, NO might also impair the ETC of the cell in which it is
produced, this being typical of M1.
Not only COX, SDH, and, as a consequence, the whole
oxidative metabolism are directly inhibited by NO (possibly
in concert with itaconate; see section IV.A.3.a), but also
PHDs are inhibited by NO, thus leading to HIF-1a stabili-
zation (87, 164, 321, 353) (see sections III and IV.A.3.a).
iNOS may also generate N-hydroxyarginine (an inhibitor of
Arg1) and the superoxide anion O2-. In addition, oxidation
and reduction of NO, as well as its reaction with oxygen or
O2-, produces several nitrogen species (among which are
nitroxyl, nitrite, nitrate, nitrogen dioxide, peroxynitrite, and
nitrosoperoxocarbonate), some of which are highly reactive
(28). In particular, peroxynitrite and nitrogen dioxide, de-
riving from the reaction of NO with oxygen, are strong oxi-
dants leading to the oxidation and nitration of proteins, lipids,
and DNA; nitrotyrosines are a major marker of nitroxidative
stress. iNOS levels and NO concentration have been sug-
gested to be lower in humans compared with rodents, and the
mix of TNFa and IFNc used for rodents might not be suffi-
cient to induce NO production in human MF in vitro (28).
Besides NO, M1 generate ROS. ROS production is asso-
ciated with high MF phagocytic activity and inflammatory
response, also leading to tissue damage along with cytokines
and chemokines. NO and ROS combine to produce highly
reactive species, thus increasing nitroxidative stress. Block-
ing ROS production inhibits the M1 inflammatory phenotype
(288, 331). Although the mechanism by which MF generate
ROS needs to be fully elucidated, ROS formation mainly
derives from NOX, mitochondria, and also from NOS; in-
deed, as stated earlier, NOS participates in the elimination of
pathogens also through direct generation of ROS (28). NOX1
to NOX5 and dual oxidases-1/2 (DUOX1 and DUOX2) are
the primary sources of ROS.
NOX are transmembrane complexes that are able to
transport electrons across membranes, thus leading to the
reduction of oxygen into superoxide O2-. When this occurs
across the phagocytic membrane, O2- is released into the
vesicles. ROS production in MF on pathogen recognition is
predominantly attributable to NOX2, whose subunits are
assembled into phagolysosome membranes on stimuli such
as IFNc and TLR activation (31, 331). Interestingly, a direct
interaction between TLR4 and NOX4 has been reported
(331). NOX2 directly produces O2-, which is converted to
other ROS, for example, its dismutated product hydrogen
peroxide (H2O2), the highly reactive hydroxyl radical (OH
)
produced by the Fenton chemistry, and associated species.
As a consequence, the targets engulfed by MF become
submerged into a mixture of toxic oxidants. NOX also con-
tribute to lowering phagolysosome pH, thus favoring the
activity of lysosomal proteolytic enzymes contributing to M1
antimicrobial action. TLR4 stimulation also leads to mito-
chondrial ROS generation from complex I through an un-
known mechanism. Moreover, in M1, another mechanism
dependent on succinate oxidation by SDH has been proposed
for ROS production (see sections III and IV.A.3.b) (214);
even the enzyme Irg1 and citrate induce ROS production (see
sections III and IV.A.3.a) (118, 140, 141).
2. NO/Arg1 and ROS in M2. After the inflammatory
phase, MF switch to the M2 phenotype and release IL-10 and
TGF-b reducing inflammation; it also reduces ROS and NO
production by upregulating, among other mechanisms, Arg1.
Arg1 is inducible and competes with iNOS for their common
substrate l-arginine to produce ornithine, polyamines, and
urea (Fig. 9) (35, 142). By limiting l-arginine availability,
cytosolic Arg1 decreases the production of NO (27, 62, 83,
217). Ornithine is the starting point of polyamine synthesis
(putrescine, spermidine, and spermine), contributing to the
stabilization of DNA and promoting collagen synthesis and
fibrosis, thus enhancing tissue repair.
Depending on the content of GSH, M1 and M2 have been
defined as oxidative and reductive MF, respectively, con-
firming crucial and specific redox mechanisms in MF (331).
Decreased ROS production, for example, by NOX2 inhibi-
tion, is necessary for M2 polarization. As stated earlier,
NADPH and ROS production is reduced by CARKL, which
contributes to M2 polarization. The interaction between MF
and apoptotic bodies triggers the binding of the protein
SYNCRIP to the NOX2 mRNA, thereby leading to its in-
stability and favoring the M2 phenotype (166); this effect is
also achieved by apocynin, an NOX inhibitor, and by muta-
tion of the NOX subunit p47phox (331). Moreover, differently
from M1, extracellular ATP seems to block IL-1b in M2 by
inhibiting inflammasome and ROS production (331).
3. Redox signaling in M1 and M2. Redox signaling in
classical versus alternative MF polarization is far for being
straightforward. Through transcription factor S-nitrosylation,
NO regulates gene expression of not only pro-inflammatory
but also respiratory chain and cell cycle genes (20). Although
it is awaiting further clarification, along with NF-jB-induced
iNOS expression there is also evidence of ROS and reac-
tive nitrogen species (RNS)-mediated NF-jB activation and
M1 polarization (28). NO activates NF-jB likely by S-
nitrosylation; however, long-lasting NO exposure reduces
NF-jB activity, contributing to M2 polarization (28, 262).
NF-jB is also modulated by ROS, as well as by AP1 and p38
MAPK (262, 277, 331); also in this case, low levels of H2O2
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enhance NF-jB activation, whereas high H2O2 levels inhibit
it (28). Moreover, IkB oxidation reduces its degradation and,
consequently, NF-jB activation, thus contributing to M2
polarization (262).
On the other hand, ROS also activate the inflammasome,
and many redox-sensitive proteins are crucial in the signaling
triggered by inflammatory mediators (14, 65, 289, 331); in-
deed, NOX inhibition favors M2 polarization (51). Although
controversial [see below Lo Sasso et al. (188)], the NAD-
dependent HDAC silent information regulator 2 (SIRT2)
seems to be involved in LPS-induced ROS generation and
NF-jB-dependent M1 gene expression, and H2O2 enhances
M1 polarization by reducing TNFR1 shedding, which would
reduce the inflammatory response [see references in Tan et al.
(331)].
ROS and RNS are, therefore, crucial both for their cyto-
toxic effects and for signal transduction.
Notably, once generated inM1, they activate inflammatory
genes but at the same time, also trigger protective mecha-
nisms that might be necessary to allow the switch to the anti-
inflammatory M2 phenotype; accordingly, a genetic defect in
ROS production induces a hyper-inflammatory response
(331). The potential role of ROS in M2 polarization is also
suggested by the inhibition of monocyte-to-M2 differentia-
tion caused by the antioxidant butylated hydroxyanisole
(396); similarly, MCP1-induced protein-mediated ROS
stimulation might be necessary for M2 polarization (155).
Moreover, the strong interaction of NO with the soluble
guanylate cyclase heme is an Fe-nitrosylation, which pro-
duces cGMP, found to be protective and anti-inflammatory.
NO also induces PPARc, which antagonizes NOX2 assembly
and attenuates NF-jB formation. This might be part of the
protective mechanisms readily activated by MF against ex-
cessive inflammation and tissue damage. In this context,
H2O2 produced by SOD1 has been found to promote M2
polarization by activating STAT6 and reducing TNFa and
iNOS expression; H2O2 acts on a critical STAT6 cysteine
leading to STAT6 nuclear translocation (128, 331). In addi-
tion, previous reports have shown with controversial results
that SOD1 modulates pro-inflammatory genes such as TNFa,
IL-1b, and iNOS and that, in other cell types, H2O2 might
increase STAT6 phosphorylation via oxidative inactivation
of the protein tyrosine phosphatase 1B (331).
Notably, free radicals produced by M1MF might also be
toxic for M1 themselves, which are, indeed, equipped to
survive the bactericidal oxidative stress occurring during
classical activation. A crucial role is played by the tran-
scription factor Nrf2 activating antioxidant genes; M1 might,
therefore, survive and persist at the sites of infection and, in
principle, switch to an M2 phenotype to allow tissue re-
modeling. MF protect themselves from radical toxicity also
by increasing the expression of DNA repair proteins and free
radical scavengers, whereas the chromatin remodeling nec-
essary to induce MF LPS tolerance is a redox-sensitive
process (13, 31, 162, 279, 337).
Further, MF protect themselves by generating many toxic
species into micro-compartments; indeed, O2- formation
mostly occurs into phagolysosomes where O2- acts against
pathogens but is separated from the rest of the cell, which is,
therefore, protected. In phagolysosomes, ROS are also sep-
arated from cytosolic NO, thus preventing the production of
highly reactive species deriving from the reaction of ROS
with NO.
Moreover, oxidation and reduction of NO convert it into
several nitrogen species whose ratio constantly changes
during M1 activation and that might represent another form
of protection from the high NO toxicity deriving by its re-
action with ROS. Protection from NO is also achieved by S-
nitrosylation of caspases, reducing the responsiveness to
apoptotic signals. Over-production of ROS in MF during
apoptotic cell phagocytosis is followed by attenuation of the
oxidative burst by PPARc activation as well as by resolvin D1
(derived from docosahexaenoic acid), which prevents MF
death and ROS production by inactivating NOX2 (150, 174).
Although controversial, NO seems to accelerate the process
of phagocytosis (304, 350). In particular, there is evidence that
on FccR stimulation of unprimed MF, nNOS and, to a lesser
extent, eNOS produce low levels of NO that promotes
phagocytosis by surrounding MF in a paracrine manner (137).
NO produced by MF is necessary for PS externalization in
dying cells through S-nitrosylation and inhibition of the ami-
nophospholipid translocase (331, 351). Conversely, in nonac-
tivated MF, NO stimulates NOX-dependent ROS generation
by increasing mitochondrial ROS, but not phagocytosis; NO
enhances mitochondrial ROS formation by inhibiting the ETC
(see section IV.C.1) (229). Intracellular ROS are also able to
increase MF phagocytic activity, and NOX2-deriving ROS
seem to be necessary for apoptotic cell engulfment (but not for
bacteria engulfment) (187, 229, 301, 331).
Extracellular ROS (mostly generated in the plasma mem-
brane even by dying cells) have autocrine and paracrine sig-
naling roles and are necessary for oxidative modification of
dying cell surface molecules (e.g., oxidation of membrane
proteins and lipids, such as phosphatidylserines), which are
eat-me signals for MF (331). Phagocytosis and ROS produc-
tion are closely linked by a common signaling pathway; in fact,
phosphatidylinositol 3,4,5-trisphosphate is necessary not only
for cytoskeleton reorganization and phagocytosis but also for
NOX activation and ROS production (123). ROS and NO are
also associated to high MF migration ability and to the con-
sequent monocyte/MF recruitment (28, 331).
Mitochondrial function is linked to their morphology,
which depends on mitochondrial membrane fusion and fis-
sion. For this reason, their shape is associated with metabolic
homeostasis and changes rapidly in response to metabolic
cues (370). Mitochondrial dynamics inMF polarization is far
from being clear; in fact, it has been shown that mitochon-
drial fission promotes pro-inflammatory TLR-induced IL-12
expression inMF and inhibits IL-10 expression through IRF1
stabilization (99) and that, controversially, defective mito-
chondrial fission augments inflammasome activation (260).
Although most of the metabolic properties of polarized MF
have been found to be a consequence of polarization, it is
conceivable, although not always proven, that these metabolic
features, if triggered inMF, would also be able to determine the
direction of polarization. This is an important issue to be un-
raveled for future applications of immunometabolic therapies.
To sum it up, high ROS and NO production due to iNOS
upregulation and Arg-1 upregulation-dependent ornithine
and polyamine production are considered molecular signa-
tures of M1- and M2 polarization, respectively. Decreased
ROS production is also necessary for M2 polarization.
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Although a dualistic MF classification in M1 and M2
subtypes with peculiar metabolic patterns is schematically
useful, the link between MF polarization and metabolism, in
particular the role of FAO, the differences between species
and between in vitro and in vivo observations, awaits further
elucidation. Indeed, as suggested earlier, polarized human
MF might have, for some aspects, different metabolic fea-
tures compared with murine MF, as observed by large-scale
transcriptomic and proteomic analyses (200), raising the
possibility of diverse immunometabolic therapeutical ap-
proaches between species. Moreover, the available infor-
mation is mainly regarding the bipolar phenotypes deriving
from in vitro LPS/IFNc- and IL-4-induced MF, whereas the
metabolic characterization of intermediate states is only at
the beginning stage.
MF polarization requires a dramatic genetic andmetabolic
re-organization, going through several steps among the pro-
inflammatory and the anti-inflammatory extremes. MF are
extremely heterogeneous, and M1 and M2 categories are an
over-simplification; in fact, M1 and M2 markers might also
be expressed at the same time. Similar to other M1 and M2
features, even their glycolytic and oxidative metabolic fea-
tures represent the extremes of a spectrum of several inter-
mediate phenotypes (359).
V. Manipulating the Metabolism to Polarize MF
Resident MF show a high plasticity and adaptation to their
microenvironment; MF polarization has been suggested to be
reversible, so that differentiated MFmight be reprogrammed
to switch from one profile to another if transferred to a dif-
ferent environment (86, 169, 170, 335). However, evidence
of in vivoM1-to-M2 repolarization is lacking; a recent in vivo
study, performed with both murine and human MF, reported
that M1 are unable to reconvert to M2, whereas M2 might be
repolarized into M1 (353). The authors found that the in-
ability to reconvert into an anti-inflammatory M2 phenotype
is caused by an OxPhos inhibition occurring in inflammatory
M1. More specifically, M1-produced NO impairs mito-
chondrial function; inhibiting iNOS during LPS/IFNc-
induced polarization recovers mitochondrial respiration and
allows M2 repolarization. Notably, although both ROS and
NO can inhibit mitochondria (87, 281), M2 polarization-
inhibition has been proposed to be specifically caused by NO,
since ROS inhibition by N-acetyl-cysteine (NAC) has no
effect (353).
Cells are very flexible in relation to the type of substrate
used; removal of a particular substrate or blocking a metabolic
route is quickly compensated by others, to obtain energy.
Metabolic changes imply a metabolic reprogramming due to
epigenetic modifications, signal transduction, and transcrip-
tional regulation; changes in metabolite levels also affect cell
state. Since metabolic changes occur during MF polarization
and metabolic intermediates are not just used to get energy but
also directly contribute to drive specific MF phenotypes, tar-
geting these metabolites to polarize MF and, possibly, to
impact on several diseases is an exciting prospect.
Various metabolic strategies are able to redirect MF po-
larization, for example, enhancing the oxidative metabolism
and protecting mitochondria allow M2 reprogramming (239,
240, 353). The metabolic sensor 5¢ adenosine monophosphate-
activated protein kinase (AMPK) activation by metformin and
5-aminoimidazole-4-carboxamide-1-b-4-ribofuranoside (AI-
CAR) with the subsequent oxidative metabolism stimulation
leads to M2 polarization also in vivo (21, 46, 239, 240, 399)
and decreases MF infiltration into the central nervous system
in multiple sclerosis mice models, thus reducing the progres-
sion of disease (239, 240). Interestingly, miR-33 drives M1
polarization by targeting AMPK (253). By contrast, it has been
suggested that metformin inhibits M2 polarization of tumor-
associatedMF (TAM), thus preventing cancer metastasis both
in vivo and in vitro, in murine and human MF (50, 71). It is
conceivable that metformin’s effect varies according to the
microenvironmental changes (46, 139).
The NAD-dependent deacetylases sirtuins also modulate
metabolism and impact MF polarization in vivo (138, 146,
153, 167, 237). By favoring oxidative metabolism, sirtuins
inhibit M1 activation being anti-inflammatory during re-
sponse against pathogens. In this context, the role of the
nicotinamide phosphoribosyl transferase, an enzyme in-
volved in NAD+ biosynthesis and sirtuin function, is crucial
also in vivo and, possibly, linked to PPARc (17, 335). SIRT3
modulates SDH activity and suppresses ROS by deacetylat-
ing and activating MnSOD (55). SIRT1 and SIRT6 favor the
M2 phenotype by switching the metabolism from glycolysis
to FA b-oxidation (186) and by inhibiting NF-jB and
STAT3, as observed in human MF cell lines and in primary
human and murine MF (48, 385). Also, SIRT2 and SIRT6
stimulate the anti-inflammatory pathway in murine MF (175,
188).
Accordingly, the flavonoid quercetin inhibits M1 polari-
zation and inflammation in high fat diet (HFD)-fed mice
through an AMPK/SIRT1-mediated mechanism (75), and the
phytoalexin resveratrol activates SIRT1 and attenuates the
inflammatory response in murine MF by inhibiting NF-jB/
ROS-mediated IL-6 secretion along with TNFa and NO
synthesis. Resveratrol promotes M1-to-M2 plasticity and M1
cell death in murine and human MF by a mechanism in-
volving Arg1 activation (53, 177, 250, 292); however, it has
controversially been reported that resveratrol inhibits TAM
M2 polarization observed in vivo in mice (323). Synthetic
SIRT1-activating compounds have been developed: They
have a greater potency compared with resveratrol; among
them, SRT1720 has an anti-inflammatory effect that acts by
reducing the number of M1 in mice (44, 48). The SIRT3
activator Honokiol inhibits iNOS expression, NF-jB and
TNFa secretion in LPS-stimulated murine MF (39).
Another molecule proposed as a metabolic modulator is
the dimethylfumarate (DMF; Tecfidera), a fumaric acid
methyl ester rapidly hydrolyzed to its active metabolite
monomethyl fumarate (MMF). DMF reduced the progression
of multiple sclerosis in a phase III clinical trial (110); since
fumarate is a TCA cycle metabolite, it might act on MF
metabolism favoring an M2 phenotype. In fact, DMF triggers
a cytokine production shift from a pro-inflammatory to an
anti-inflammatory pattern, inducing an M1-to-M2 phenotype
shift in vitro. In particular, in LPS/IFNc-treated human pe-
ripheral blood mononuclear cells, the expression of CXCL8,
CXCL9, and CXCL10 chemokines is inhibited by DMF;
whereas MMF-treated ones upregulate the anti-inflammatory
IL-4, IL-5, IL-10, and IL1-ra (248, 335). Although contro-
versial, DMF is categorized as anti-inflammatory by possibly
activating the transcription factor Nrf2 inducing antioxidant
genes (335).
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Consistent with the earlier considerations, PDK1 plays a
key role in in vitro murine MF polarization (332); it phos-
phorylates and inhibits some components (e.g., PDH-E1a) of
the PDH complex, converting pyruvate derived from gly-
colysis to acetyl-CoA. Acetyl-CoA, in turn, enters the Krebs
cycle, thus generating NADH and FADH2 fueling the ETC
for OxPhos. PDK1 promotes M1 polarization, enhances
glycolysis and lactate production, and inhibits M2 (332).
Moreover, its downregulation decreases glycolysis and lac-
tate production in response to TLR activation while in-
creasing mitochondrial respiration; it also reduces IL-6 and
iNOS mRNA levels as well as iNOS and COX-2 protein
levels, therefore decreasing the induced M1-inflammatory
response (332).
As reported earlier, PPARc is crucial for alternative MF
activation (47, 249, 258, 259). Also, PGC-1b promotes M2
polarization through IL-4 and STAT6 in BMDM, while
stimulating FAO and mitochondrial biogenesis (357). The
energy production coordinator PGC-1a promotes oxidative
metabolism; it is upregulated in M2, and its over-expression
stimulates M2 polarization (72).
MF polarization is also influenced by FA-induced meta-
bolic reprogramming; different FAs exert different effects on
MF polarization, for example, human MF incubated with the
saturated FA palmitate, but not with oleate, stimulate inflam-
matory cytokines and ROS production inducing M1 polariza-
tion and reducing OxPhos dependency through ceramide-
dependent PPARc inhibition (259). Vice versa, the omega-3
FA eicosapentaenoic acid (EPA) increases IL-10 and reduces
INF-c levels, thus promoting an M1-to-M2 shift in mice (33).
Similarly, other lipid derivatives such as lipoxins and palmi-
toleic acid have anti-inflammatory effects (287).
In obesity, adipose tissue is characterized by infiltrating
pro-inflammatory MF; high levels of circulating FA might
trigger M1 polarization in the adipose tissue of obese indi-
viduals. The effect of modulating FAO in the presence of
high levels of FA is still unclear; activating FAO in MF
might be beneficial since it metabolizes FA, an anti-
inflammatory effect. On the other hand, it has been shown
that palmitate oxidation fuels OxPhos and produces ROS,
thereby activating the inflammasome and pro-inflammatory
cytokines production.
As discussed earlier, hypoxia-activated HIF-1a induces
iNOS and IL-1b; moreover, the effect of HIF-1a on glucose
uptake potentiates glycolysis and pro-inflammatory activity, as
observed in cultured human and murine MF and in a murine
model of atherosclerosis (143, 338). More recently, it has been
found that HIF-1a leads to increased mitophagy, which, in
turn, induces a metabolic reconfiguration toward glycolysis,
causing M1 polarization (85). Notably, intramuscular pO2 is
lower compared with atmospheric oxygen levels even in
physiological conditions; since pO2 influences cell physiology,
data obtained in vitro might not fully reproduce in vivo pro-
cesses also for this reason, even though M1 and M2 metabolic
features occur in different tissue pO2 conditions.
In conclusion, these data emphasize the potentiality of
metabolic therapies in directing MF activation.
VI. MF and Skeletal Muscle Regeneration
Besides their role in innate immunity, MF are also in-
volved in tissue repair (108, 180, 201). In particular, we will
hereby describe the crucial role of MF in allowing efficient
skeletal muscle regeneration (245); the muscular regenera-
tive program is first illustrated, followed by the analysis of the
role of MF in regeneration on acute injury and chronic
muscle diseases. In particular, the relevance of the M1-to-M2
switch and the interaction between MF subsets, satellite cells
(SCs), and other muscle resident or infiltrating cells is dis-
cussed.
A. Skeletal muscle regeneration
In response to skeletal muscle damage, a finely regulated
regeneration program is rapidly activated to allow muscle
recovery (339). Muscle regeneration relies on proliferation
and differentiation of SCs, the muscle resident stem cells
localized under myofiber basal lamina usually quiescent
during homeostasis (205, 389). In response to muscle dam-
age, in both acute and chronic conditions, SCs exit from
quiescence and undergo proliferation followed by either
asymmetric division-mediated commitment to terminal
muscle differentiation or return to quiescence as part of the
SC pool (40).
SC asymmetric division guarantees that SC number does
not change on multiple regenerative events, thus maintaining
the muscles’ regenerative potential (374). The ability of SCs
to stay in a quiescent state is essential for SC self-renewal and
maintenance of muscle stem cells pool (19, 227). Quiescence
is a regulated condition, characterized by the expression of
negative cell cycle regulators such as p27Kip1 and retinoblas-
toma tumor suppressor protein (Rb) (36).
Several markers for SCs and regenerating myofibers have
been identified. Quiescent SCs specifically express Pax7
(306); SC activation is induced by mitogenic factors released
in the damaged muscle area, such as insulin-like growth
factor-1 (IGF-1), which downregulate p27Kip1, allowing cell
cycle entry (37). Activated SCs (Pax7+, Myf5+) are also
characterized by MyoD expression, typical of proliferating
myoblasts that are able to undergo both self-renewal and
differentiation.
Myoblast commitment to terminal muscle differentia-
tion—involving Wnt and Notch pathways—is characterized
by Pax7 downregulation and induction of early and late
muscle regulatory factors (MRFs), specifically Myogenin
and MRF4/Myf6 (25, 58). At this stage, differentiating
myocytes fuse with pre-existing myofibers or with each
other, to generate multinucleated myotubes expressing em-
bryonic myosin heavy chain (MyH3/eMyHC) and undergo-
ing further fusion with neighboring myotubes to produce
myofibers (339).
Newly formed myofibers can be distinguished by their
small caliber, by eMyHC expression, and by centrally located
myonuclei; whereas mature myofibers have bigger diame-
ters, express different isoforms of adult MyHC (Myh1/fas-
tMyHC2x, Myh2/fastMyHC2a, Myh4/fastMyHC2b, Myh7/
slowMyHC1,Myh8/perinatal MyHC) (305) along with other
late differentiation markers (e.g., muscle creatine kinase) and
their nuclei are peripherally located (Fig. 11) (54, 393). Re-
generating myofibers express the same MyHC isoforms that
are characteristic of the specific damaged muscle, in both
acute and chronic injury (305).
A detailed histopathological analysis of several regenera-
tive stages on acute injury is shown in Figure 12A, whereas
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immunofluorescence detection of MF and newly formed
myofibers is shown in Figure 13A. The scheme in Figure 14
shows the timing and trend of MF recruitment after muscle
injury in parallel with the different muscle repair stages in
which they are involved (125).
B. Role of MF in skeletal muscle regeneration
Muscle infiltrating immune cells play a critical role in
skeletal muscle regeneration; neutrophils and MF are very
abundant in damaged muscles, as observed in human biopsies
and in mice (6, 93, 340, 342), whereas eosinophils (129) and
lymphoid cells (CD4+, CD8+, and regulatory T cells/Treg)
are rare although relevant for successful regeneration (29, 34,
367). However, a definitive understanding of the complex
temporally coordinated MF roles in acute injury and in
muscle degenerative diseases, and of the mechanisms regu-
lating the crucial MF polarization occurring in regeneration,
is still lacking (158, 296, 366).
As stated earlier, MF are able to assume, in response to a
large variety of stimuli, a wide spectrum of polarization
statuses corresponding to defined transcriptome signatures
(386). Although the gross in vitro M1/M2 classification, in-
cluding M2 subtypes, is schematically useful, it represents a
conventional description that does not exhaustively recapit-
ulate the in vivo process and the MF milieu in regenerating
muscle, characterized by cell-to-cell interactions and by
several uncharacterized MF phenotypes intermediate be-
tween M1 and M2 subtypes (142).
1. On acute injury. After injury, the number of MF
within the skeletal muscle (located in the interstitial space of
regenerating muscle) exponentially increases; damaged
myofibers undergo necrosis; and release of normally muscle-
compartmentalized factors recognized by TLRs triggers the
production of pro-inflammatory cytokines and chemokines,
including CCL2, which recruit bone marrow-derived mono-
cytes (Ly6C+CCR2+CX3CR1low) into damaged muscles. In
murine models of muscle injury, monocytes differentiate into
highly plastic MF (Figs. 1 and 2) that, in response to cues
from a damaged environment, polarize toward M1/Ly6C+
and M2/Ly6C- phenotypes mounting and resolving the in-
flammatory response, respectively (6, 224, 319).
Blocking MF recruitment to damaged muscles in the first
24 h after injury impairs muscle regeneration, increasing
necrotic fibers and fat deposition, as revealed in transgenic
FIG. 11. Muscle regeneration process relies on SCs. During muscle homeostasis, SCs are maintained in a quiescent
state by the activity of negative regulators of proliferation. In response to muscle injury, SCs undergo activation, exit from
quiescence, and enter the cell cycle while undergoing symmetric or asymmetric divisions. Some daughter cells return to
quiescence as part of the SC pool (self-renewal); several daughter cells activate a muscle differentiation program regulated
by specific signaling pathways and leading to the expression of both early and late muscle regulatory factors (Myf5, MyoD,
Myogenin, Myf6/MRF4). Differentiated myocytes fuse with each other and with pre-existing myofibers to generate new
multinucleated myotubes that express embryonic myosin heavy chain (MyH3/eMyHC) and undergo further fusion with
neighboring myotubes to produce mature myofibers expressing different isoforms of adult MyHC and other markers of
terminal differentiated fibers (such asmCK), determining regeneration of damaged muscle areas. eMyHC, embryonic
myosin heavy chain; mCK, muscle creatine kinase; SCs, satellite cells.
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mice expressing the diphtheria toxin receptor (DTR) under
the CD11b promoter control (CD11b-DTR mice), so that
CD11b+ cells (mainly MF) might be depleted on diphtheria
toxin injection (6, 374). Moreover, studies in mice high-
lighted the crucial role of MF infiltration in muscle regen-
eration, which is impaired by genetic deletion of CCR2
(CCL2 receptor) or CCL2, both causing lower MF recruit-
ment (191, 197, 311, 376).
Experiments in mice suggest that monocyte recruitment
occurs as a result of an early activation of resident MF
FIG. 12. Histopathological analysis of skeletal muscle regeneration on acute and chronic injury. H/E and Sirius red
(specific for collagen isoforms) stainings performed on TA cryosections highlight skeletal muscle architecture and ECM
deposition, respectively. (A) Time course of muscle repair on injection of CTX in TA muscles (uninjured control muscle-
Ctrl, CTX day 3, CTX day 7, CTX day 10, and CTX day 21). At early stages of regeneration on acute injury (day 3 after
CTX injection), H/E reveals a massive muscle infiltrate along with necrotic fibers (x) in the damaged area. The intermediate
stage of muscle regeneration (day 7 on CTX injection) is characterized by huge ECM deposition (Sirius red staining) and
small regenerating centro-nucleated myofibers (*), indicating an engagement in the muscle regeneration process. At a more
advanced stage of CTX-induced regeneration (day-10), the majority of regenerating myofibers are bigger (due to increased
size) although still centro-nucleated, whereas interstitial infiltrate and collagen deposition are strongly reduced and,
eventually, completely disappear at a late stage of regeneration (day 21 on damage) when regeneration appears almost
completed and is mainly characterized by mature myofibers with peripherally located nuclei just beneath the sarcolemma,
even though few regenerating centro-nucleated fibers are still detectable. On an acute injury, inflammatory infiltration and
collagen deposition are transient and the regenerative process culminates in a complete regeneration of the damaged area
with an overall recovery of muscle architecture, reduced interstitial space, and no detectable MPs and regenerating myo-
fibers. Scale bar = 200 lm. (B) Muscle regeneration of dystrophic TA muscle from mdx mice at different stages of disease:
6, 12, and 36 weeks, corresponding to necrotic/inflammatory, regenerative, and fibrotic phase of dystrophic pathology,
respectively. Young mdx mice (6 weeks old) show several centro-nucleated regenerating fibers, low inflammatory infiltrate,
and collagen deposition that are necessary to support muscle regeneration and proper compensatory recovery of muscle. TA
muscles of 12-week-old mdx mice (corresponding to the regenerative phase of DMD) are quite comparable to day 7 after
CTX-induced damage (A), in terms of centrally nucleated fibers, inflammatory infiltrate, and ECM deposition. Differently
from acute injury, which culminates in a complete regeneration of the damaged muscle (A), at the late stage of chronic
disease (36-week-old mdx mice), the muscle architecture appears more damaged, with persistent inflammatory infiltration,
reduced although still detectable and regenerating centro-nucleated fibers and irreversible accumulation of collagen, leading
to increased fibrosis. Scale bar = 200 lm. CTX, cardiotoxin; DMD, Duchenne muscular dystrophy; ECM, extracellular
matrix; H/E, hematoxilin/eosin; TA, tibialis anterior. To see this illustration in color, the reader is referred to the web
version of this article at www.liebertpub.com/ars
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(Ly6C+CX3CR1-) releasing chemoattractants CXCL1 and
CCL2, determining a massive neutrophil influx, in turn re-
sponsible for Ly6C+CCR2+CX3CR1low circulating mono-
cytes extravasation toward damaged skeletal muscle (26,
340). The involvement of muscle-resident MF in regenera-
tion is still obscure; transplantation of WT DT-insensitive
bone marrow cells in CD11b-DTR mice—used to deplete
MF and to discriminate between muscle-resident and re-
cruited MF—demonstrated that muscle-resident MF are
involved in monocyte recruitment after muscle damage (42).
On the other hand, if MF recruitment to the muscle is
blocked (for example in CCR2-/- mice), the muscle fails to
regenerate, suggesting that resident MF are only poorly
involved in regeneration (60, 376), possibly due to the low
number of MF residing in skeletal muscles in physiolog-
ical conditions (6).
Besides neutrophils, T cells have also been implicated in
monocyte/MF recruitment via the CCL2/CCR2 axis; they
contribute to CCL2 production and proper regeneration (394).
Moreover, Treg rapidly accumulates in acutely injured and
dystrophic muscles, ameliorating muscle repair by suppressing
inflammation and enhancing SC expansion (29, 34, 367).
a. M1-to-M2 switch in muscle regeneration. The early steps
ofmuscle regenerationareassociatedwithpro-inflammatoryM1
deriving from recruitedmonocytes (Ly6C+CCR2+CX3CR1low),
whereas later on, the intermediate-late steps of regeneration, in
mice, are associatedwith Ly6C-CX3CR1high anti-inflammatory
M2. M1 promote phagocytosis of necrotic fibers and debris,
sustain inflammation, and support activation and proliferation
of SCs during early regeneration; whereas M2 promote the
resolution of inflammation and enhance muscle regeneration
by inducing muscle progenitor cells (MPCs) differentiation
(194, 291).
Recently, a gene expression analysis onmurineMF, sorted
as GFP-positive cells from CX3CR1GFP/+ mice at four sub-
sequent time points after cardiotoxin (CTX)-induced muscle
damage, revealed highly dynamic changes in MF expression
profile in response to injury (356) at different steps of re-
generation: (i) Ly6C+-MF show an IFNc-independent in-
flammatory profile; (ii) a glycolytic-to-oxidative metabolism
switch sustains the anti-inflammatory M2 polarization; (iii)
Ly6C--proliferating MF highly express M-CSF, and the
administration of anti-M-CSF-receptor antibody during
muscle regeneration suppresses MF—but not neutrophil—
FIG. 13. Regenerating myofibers and MP infiltration on acute and chronic injury. Immunofluorescence staining of
TA muscle cryosections (similar to those used for Fig. 12), using antibodies recognizing eMyHC as a marker of newly
formed myofibers (red) Laminin (green) to label myofiber perimeter and F4/80 (cyan) as a surface marker of MPs. Nuclei
were stained with DAPI (white). Scale bar = 100lm. (A) Time course of CTX-injected TA (uninjured control muscle-Ctrl,
CTX day 3, CTX day 7, CTX day 10, and CTX day 21). At an early phase of regeneration after CTX injection (day 3), a
massive inflammatory infiltrate is detectable and is mainly represented by F4/80+ MPs (cyan) (see also day 7). At an
intermediate phase of regeneration (CTX day 7), several newly formed myofibers can be readily distinguished by their small
caliber, by a huge expression of eMyHC (red), and by their centrally located myonuclei. These markers almost completely
disappear at a later stage of regeneration (day 10) and become undetectable later on (day 21), where some fibers show
peripherally located nuclei. (B) Muscle cryosections of TA from mdx mice at different stages of disease: 6, 12, and 36
weeks, corresponding to necrotic/inflammatory, regenerative, and fibrotic phase of dystrophic pathology, respectively. The
early stage of pathology is characterized by low level of eMyHC+ regenerating fibers (red) (arrows), several centro-
nucleated regenerating fibers, and low level of F4/80+ MF (cyan). In 12-week-old mdx mice, regenerating fibers (char-
acterized by huge expression of eMyHC) and massive MF infiltration (F4/80+ cells) are abundant in dystrophic muscles and
are similar to injured muscles at the intermediate phase of regeneration (day-7 CTX injection). Dystrophic muscles are
characterized by chronic inflammation, and, indeed, MF are still abundant in 36-week-old mice and muscle regeneration is
reduced but still detectable (some eMyHC+ fibers and centro-nucleated but small myofibers). To see this illustration in
color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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infiltration and compromises muscle repair, affecting SC
proliferation and differentiation and increasing fibrosis (307);
and (iv) Ly6C--MF produce secretory ECM-related mole-
cules involved in intercellular communication and regenera-
tion, such as matrix metalloproteinase-2 (MMP2).
A sequentially synchronized recruitment and activity of
different MF subtypes, with an M1-to-M2 shift, is required
for successful muscle regeneration (6, 372); in fact, chronic
M1 activation exacerbates muscle injury by releasing medi-
ators of cell damage and cytokines amplifying inflammation.
For this reason, in parallel or soon after any inflammatory
response, mechanisms aimed at reducing inflammation are
activated; M2 anti-inflammatory cytokines, such as IL-10,
inactivate pro-inflammatory genes and further drive MF-
alternative activation (364).
The transition from the early M1 immune response to the
intermediate-late M2 immune response is, therefore, required
and, functionally, corresponds to the progression of the
myogenic regenerative program, since M2 stimulate myo-
genic differentiation and promote myocyte fusion (297). In-
terference with M2 polarization is detrimental on muscle
regeneration, and in vitro polarized MF and FACS-isolated
Ly6C--MF are beneficial when transplanted into injured
skeletal muscle (294, 344, 372).
However, the cause of the sequential presence of M1 and
M2 in the damaged area of skeletal muscle is still a matter of
debate; it is not clear whether skeletal muscle M1 are able to
repolarize to M2, due to changes in the damaged microen-
vironment, or whether new Ly6C-CCR2-CX3CR1+ mono-
cytes are recruited, at later stages, to a repair-promoting
environment (e.g., when CX3CL1/fractalkine attracting M2
is produced by resident MF due to interaction with dying
cells) where they differentiate to M2, as further suggested by
selective depletion of Ly6C- monocytes enhancing M1
generation (102, 103, 116, 121).
By contrast, a pivotal paper, first describing the M1-to-M2
polarization within muscle as dependent on necrotic muscle
phagocytosis, supports the hypothesis of MF phenotypic
transition within muscle by which injured skeletal muscle
recruits only pro-inflammatory monocytes (Ly6C+CCR2+
CX3CR1low) that, within muscle, switch phenotype to be-
come proliferating anti-inflammatory Ly6C-CCR2+CX3
CR1high cells, further differentiating into F4/80+ MF (6).
Moreover, the MAPK-phosphatase-1 (MKP-1)-p38-Akt axis
is crucial for sequential M1-to-M2 transition, and deregula-
tion of MF skewing by MKP-1-loss, in mice, results in im-
paired SC activity and defective regeneration (268).
Also, AMPKa1 is crucial for phagocytosis-induced pro-to-
anti-inflammatory MF skewing, at the time of inflammatory
resolution; indeed, damaged muscles of AMPKa1-/- mice
show decreased M2 and increased M1 subsets, along
with regenerative impairment (226). In addition, CCAAT
FIG. 14. Timeline of recruitment and activity of immune cells during skeletal muscle regeneration on acute injury.
Immune cells are sequentially recruited during the regenerative response, starting from the pro-inflammatory phase,
characterized by cell debris removal and activation of SCs and other resident cells, and culminating with activation of the
anti-inflammatory program that sustains MPC differentiation and recovery of muscle architecture and function. In vivo
experiments demonstrated that granulocytes, in particular neutrophils, are rapidly recruited and infiltrate the damaged area
in a few hours, reaching the peak between 12 and 24 h from the event of injury. They are mainly responsible for
maintenance of inflammation and recruitment of other immune cells. Later (between 1 and 2 days postinjury), monocytes
reach the injury site and differentiate toward pro-inflammatory M1MF (2/3 days postinjury) that are responsible for
removal of cell debris and stimulation of SCs proliferation (in vitro experiments). M1 are followed by anti-inflammatory/
pro-myogenic M2 (between 3 and 7 days postinjury), supporting SCs differentiation (in vitro experiments). To note, the
graph is a schematic representation typical of CTX-injury; however, it does not take into account the specific timeline
variability, which, indeed, is associated to different injury signals and also to different concentrations of the same damage
stimulus (125). MPC, muscle progenitor cell.
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enhancer-binding protein (C/EBP)b in infiltrating MF is
required for the upregulation of M2-specific genes and for
M1-to-M2 switch and muscle regeneration (210, 291). The
critical role of the MF-phenotypic switch for regeneration
is also confirmed by the recent finding that miRNA-155
expression in myeloid cells modulates MF activation
in vivo in mice and is necessary for proper muscle regen-
eration; during the initial inflammatory phase, miRNA-155
suppresses SOCS1 (a negative regulator of the JAK/STAT
pathway) (243).
Also, in human skeletal muscle regeneration, different MF
subsets modulate MPC fate; specifically, pro-inflammatory
M1 are mainly associated with regenerating areas containing
proliferating myogenic cells, whereas M2 are preferentially
associated with differentiating myogenic cells (297). Among
the different anti-inflammatory M2 subtypes, M2a are
associated with halted muscle regeneration, collagen ac-
cumulation, fibrogenesis, and angiogenesis, preceded by
anti-inflammatory M2c involved in tissue remodeling and
regeneration, ECM deposition, and immunoregulation. As
reported earlier, under the effect of IL-10, M2c express re-
ceptors for pro-inflammatory chemokines, which would
possibly serve as a scavenger receptor system to dampen
inflammation (270).
2. In chronic muscle diseases: for example, Duchenne
muscular dystrophy. Similar to acute injury, also at early
stages of neuromuscular disorders, such as Duchenne
muscular dystrophy (DMD), muscle regeneration com-
pensates chronic degeneration. However, differently from
acute injury, chronic muscle diseases are characterized by
overlapping and asynchronous cycles of degeneration and
regeneration, associated with continuous MF infiltration
producing, at each stage of disease, a mixed MF population
containing variable levels of MF subtypes. The balance
between different MF subpopulations is determinant for
the progression of dystrophy in mdx mice, the commonly
used mouse model of DMD disease (364).
For instance, the competition between iNOS-producing
M1 and Arg1-producing M2a influences the extent of myo-
fiber lysis by MF. In fact, M2a reduces the cytolytic activity
ofM1 (363–365). BothM1 andM2a are present in muscles of
4-week-old mdx mice, the acute necrotic stage of the pa-
thology (364). Arg1 expression in M2 increases in mdx
muscles as dystrophy proceeds, and Arg1 metabolism might
contribute to fibrosis driven by M2 in response to Th2 cyto-
kines; indeed, ablation of Arg1 reduces fibrosis (377).
In DMD patients, the dystrophic pathology onset coincides
with the onset of muscle inflammation, suggesting a key
detrimental role of inflammatory cells in the progression of
DMD and other skeletal muscle degenerative diseases char-
acterized by chronic inflammation (366). The inflammatory
progression in DMD patients is similar to what is observed in
mdx mice. To study the role of MF in DMD, we recently
generated an MF-depleted dystrophic mouse model by
crossing the CD11b-DTR mouse with the mdx one, and we
have confirmed the crucial beneficial role of MF in muscular
dystrophies (unpublished observations).
A detailed histopathological analysis of various stages of
skeletal muscle regeneration on chronic injury is shown in
Figure 12B. Specific markers, identified by immunofluores-
cence, show that 12-week-old mdx mice muscles are similar
to CTX-injured muscles at the intermediate phase of regen-
eration (day-7 CTX injection) (Fig. 13A, B) [reviewed in
Rigamonti et al. (282)].
C. Cross-talk between metabolically diverse
MF subpopulations and muscle resident cells
MF affect myogenesis and muscle fibrosis, after acute
damage and in chronic diseases, by producing cytokines,
chemokines, soluble factors, and cross-talking with muscle
resident cells, for example, fibroadipogenic progenitor cells
(FAPs), fibroblasts, SCs, and endothelial cells (218, 275). A
reciprocal cross-talk between muscle cells and infiltrating
immune cells also occurs, with muscle cells responsible for
modulating the MF phenotypic shift during repair (261).
The proper interplay among different cell types ensures
phagocytosis of necrotic myofibers, activation of SCs, ex-
ecution of the myogenic program (6), angiogenesis (247),
and SC self-renewal to restore stem cell pool (225), thus
forming new functional myofibers and allowing muscle
homeostasis.
MF participate in the final stages of skeletal muscle re-
pair by releasing not only anti-inflammatory mediators,
such as TGF-b and IL-10, but also pro-regenerative and pro-
angiogenic growth factors such as IGF-1 and VEGF-A, fi-
broblast growth factor (FGF), placental growth factor, and
hepatocyte growth factor (HGF). Also, SDF-1 is necessary
for collagen deposition into the damaged muscle and for re-
generation (287), and through polyamine and collagen syn-
thesis M2-produced ornithine promotes cell proliferation,
fibrosis, and tissue remodeling (272). MF-produced growth
factors act on the ECM, triggering angiogenesis; MF also re-
lease MMP2 and urokinase-type plasminogen involved in
ECM protein degradation and proteolytic activation of HGF
[reviewed in Rybalko et al. (294)], whereas collagen VI is also
critical for MF migration and M2 polarization in mice (47).
Apoptotic cell clearance also contributes to triggering M2
activation and wound healing. Moreover, in response to
sterile injury, vessel-associated stem cells (mesoangio-
blasts) specifically upregulate genes involved in the clear-
ance of apoptotic cells and in M2 polarization—such as
CD163—in MF (23). Notably, MF-secreted complement
C1q impairs regeneration; blocking the angiotensin-II type
1 receptor by irbesartan induces M2 polarization and re-
duces MF-associated C1q expression, thus ameliorating
regeneration and reducing fibrosis (387).
Immune system-produced ROS also participates in tissue
repair key signaling and could be beneficial or detrimental
depending on their levels. For example, ROS modulate the
release of pro-inflammatory cytokines by modulating the
balance between reduced and oxidized HMGB1 forms, in-
volved in SC activation and differentiation in damaged
skeletal muscle (358). However, excessive ROS levels can
hyper-activate the inflammatory response, thus impairing
regeneration. It has been suggested that MF-derived ROS are
not involved in skeletal muscle regeneration (171); vice versa,
iNOS seems to be crucial in acute muscle damage in vivo,
indeed NO stimulates muscle repair (59), and M2 express
factors such as SOD1 and thioredoxin that are implicated in
HMGB1 reduction (360). A comprehensive analysis of redox
regulation in resident and infiltrating cells during skeletal
muscle regeneration is reviewed in Le Moal et al. (172).
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The cross-talk between MF and SCs and between MF and
FAPs will be discussed (Fig. 15).
1. Cross-talk MF: SCs. At early stages of regeneration,
the cross-talk between SCs and MF is mainly modulated by
M1-produced pro-inflammatory cytokines, which further
recruit immune cells that are responsible for fiber debris
and necrotic cell phagocytosis regulating, in an autocrine
manner, the balance between MF subpopulations. Pro-
inflammatory mediators also exert paracrine effects on
muscle cells, for example, activating quiescent SCs that
start proliferating, as observed in mice and in humans, and
regulating FAP fate (43, 297, 343). In fact, SCs/MPCs
proliferation was found to be associated with M1, both
in vivo and in vitro; M1 migrate toward SCs/MPCs, where
they stimulate their proliferation and prevent their prema-
ture differentiation (Fig. 16) (297).
As described in mice, after the phagocytic phase, an M1-
to-M2 switch occurs, with M2 inhibiting M1 and reducing
pro-inflammatory cytokines-mediated MPCs proliferation
while stimulating their differentiation (70).
IFNc rapidly increases in injured muscle; it binds to its
receptor expressed by both M1 and SCs/MPCs and activates
target genes via JAK-STAT1 (49, 190, 222). As observed in
mice, IFNc promotes M1 polarization and represses SCs/
MPCs differentiation by inhibiting myogenic genes— for
example, Myogenin—through recruitment of Jarid2 and
polycomb repressive complex-2 to their promoters (190, 381).
Early in regeneration, IFNc signaling maintains the M1 phe-
notype, allowing MPCs expansion; however, at intermediate-
late stages of regeneration, IFNc signaling must be switched
off to avoid terminalmuscle differentiation impairment (Fig. 16)
(190). IFNc ablation in mdx mice modulates the M1/M2
balance, this having different consequences at the inflam-
matory (3–4 weeks of age) and regenerative stages (6–12
weeks of age) of disease. The early inflammatory stage was
not affected by IFNc ablation, suggesting that M1 polari-
zation is not strictly dependent on IFNc.
By contrast, at the regenerative stage, IFNc deletion is
beneficial in that it promotes pro-regenerative M2 polariza-
tion and increases MyoD expression (363). Similar to IFNc,
TNFa acts both on MF, promoting M1 polarization, and on
MPCs, affecting regeneration (Fig. 4). TNFa induces tran-
scriptional repression of specific muscle genes (Pax7,MyoD,
Myogenin, and MEF2C) in MPCs by Ezh2 recruitment on
promoters (1, 58, 255). IL-6, TNFa, IL-1b, and G-CSF are all
known to enhance myogenic proliferation (41, 122).
The anti-inflammatory cytokine IL-10 is crucial for the
M1-to-M2 switch, improving muscle regeneration in both
acutely injured and dystrophic muscles (Fig. 4) (70, 365). IL-
10 effect on M2 polarization depends on IL-10-mediated
AMPK activation, critical for the glycolytic (predominant in
M1) to the oxidative metabolism (predominant in M2)
switch, as observed in vitro (399). Indeed, AMPKa1 deletion
in myeloid cells delays muscle repair, likely by influencing
MF polarization (226). Although demonstrated only in vitro,
IL-10-expressing M2 might also promote myoblast prolifer-
ation (70).
Moreover, M2-dependent IL-10 production is essential to
support mesoangioblast survival and function in vivo (24).
IL-4, mainly produced by eosinophils and Th2 cells, con-
tributes to promoting M2 polarization, thus creating a pro-
regenerative environment (Fig. 16). IL-4 is also expressed by
muscle cells and controls myoblast/myotube fusion; it is se-
creted by myotubes and binds to myoblast-expressed IL-4R,
therefore recruiting myoblasts to myotubes. IL-4 is regulated
FIG. 15. Cross-talk be-
tween resident and infil-
trating cells during skeletal
muscle regeneration. Gra-
phical schematization of a
transversal section of skeletal
muscle. Several resident and
infiltrating cells support re-
generative myogenesis; only
SCs in their sub-laminar lo-
calization, and FAPs and MF
in the interstitial area be-
tween muscle fibers are re-
presented. Gray arrows
indicate cell interplay and
define the directionality of
interactions among these
three cell populations. FAPs,
fibroadipogenic progenitor
cells.
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by the transcription factor NFATc2, crucial for myoblast
fusion (132).
Produced by several resident cell types or ones infiltrating
the regenerative muscle, TGF-b, crucial for muscle regen-
eration, is abundant in acutely injured muscles and in muscles
of mdx mice and DMD patients [reviewed in Duffield et al.
(78)]. In dystrophic muscles, anti-inflammatory TGF-b is
mostly produced by M2 (273, 398). M2-secreted TGF-b
supports the formation of myotubes (297). However, exces-
sive levels of TGF-b2, induced by elevated canonical Wnt
signaling in dystrophic muscles, affect SC fate, which un-
dergoes fibrogenic conversion (Fig. 16) (18). TGF-b1 can
cause fibrosis and neutralizing it significantly promotes
muscle regeneration, enhances angiogenesis, prolongs SC
activation, and recruits a greater number of M2. If MF in-
filtration is compromised, endothelial-derived progenitors
undergo an endothelial-to-mesenchymal transition, possibly
triggered by TGF-b, collagen accumulates, and the muscle is
replaced by fibrotic tissue (400).
In regenerating muscle, both M1 and M2 produce IGF-1,
although it is more prominently expressed by M2 (191). IGF-1
is a potent regeneration enhancer and is upregulated during
the inflammation-to-repair transition phase (12, 235). MF-
derived IGF-1 influences muscle regeneration by a double
action: by acting on myogenesis, increasing MPCs prolifer-
ation and boosting their terminal differentiation, and in an
autocrine manner, by inducing a pro-regenerative M2 po-
larization and contributing to resolve inflammation (346).
Indeed, IGF-1 deletion in myeloid cells impairs M2 accu-
mulation, thus compromising in vivo regeneration (346).
By means of released factors such as IGF-1, MF also act
on intra-myocellular processes that are crucial during re-
generation, such as protein synthesis; IGF-1 promotes myo-
fiber protein synthesis predominantly by activating the
phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway and
phosphorylating 4E-BP1 and S6K1 (12, 235). Notably, the
PI3K/Akt/mTOR pathway also mediates autophagy, which
might, therefore, in principle, be modulated byMF-produced
FIG. 16. MF affect SCs and FAPs cell fate during skeletal muscle regeneration. Graphical schematization of the
cross-talk through soluble factors (chemokines, cytokines, growth factors, small molecules, or structural proteins) between
SCs, FAPs, and MF. The upper part describes the activation of SCs in response to damage signals: SCs exit from
quiescence and undergo a proliferative phase followed by commitment into terminal muscle differentiation, or they return to
quiescence to maintain the stem cell pool. Differentiating myocytes fuse with pre-existing myofibers or with each other to
originate new multinucleated myotubes that further fuse with neighboring myotubes to produce mature myofibers. A
schematic simplification of MF and activated MF subtypes in regenerating skeletal muscle is described next: M1 polarized
by pro-inflammatory cytokines such as IFNc and TNFa; M2 polarized by anti-inflammatory cytokines such as IL-4 and IL-10.
M1 produce soluble factors, such as IFNc, TNFa, IL-1, IL-6, NO, and ROS, that contribute to SCs activation and
proliferation. Factors derived from M2MF (such as IL-4, IL-10, IGF-1) mainly influence myocyte differentiation. MF also
affect FAPs cell fate, represented in the lower part, modulating the balance between FAPs, apoptosis, and differentiation
toward fibrogenic or adipogenic lineage. On the other hand, FAPs support SCs differentiation during physiological skeletal
muscle regeneration by transient deposition of ECM. In pathological conditions, such as muscular dystrophies, the per-
sistence of activated FAPs in the damaged muscle area has been associated with increased and irreversible production of
collagen, replacement of muscle fibers with fibrotic scars, and fat deposition leading to an exacerbation of the degenerative
muscle phenotype. Thick arrows represent the progression of cell differentiation or polarization; thin arrows represent the
soluble factors (cytokines, chemokines, growth factors, small molecules, or structural proteins) affecting the fate of target cells.
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IGF-1 (286). IGF-1 is also produced by muscle cells on ex-
ercise; it might have a trophic action, possibly even physio-
logically, independently from the occurrence of inflammatory
conditions (265). Also, IL-6 might act on the Akt/mTOR
pathway, influencing protein synthesis and, presumably,
autophagy; however, controversial results suggest oppo-
site roles for IL-6 in the regulation of muscle fiber size and
regeneration (10).
Notably, after muscle injury, MF secrete the metallopro-
teinase Adamts1, which targets and impairs Notch signaling,
thus strongly increasing SC activation (77). Moreover, in
mice, damaged myofibers and infiltrating MF release the
protein S100B, which expands the myoblast population and
promotes M2 polarization modulating collagen deposition.
However, prolonged high levels of S100B compromise
regeneration by delaying the M1-to-M2 transition and
promoting fibrotic tissue deposition (283). Interestingly,
anti-inflammatory M2-expressed CD163 is a receptor and
scavenger for the cytokine TNF-like weak inducer of apoptosis
(TWEAK). A soluble portion of CD163 functions as a decoy
receptor for TWEAK, regulating its ability to activate Notch
signaling and stimulate MPCs proliferation and tissue re-
generation (3).
SCs recruit monocytes/MF using various chemotactic
systems that are also useful to reduce apoptosis [reviewed by
Rybalko et al. (294)]. The chemotactic factor CX3CL1 is
produced by resident MF on interaction with dying cells and
is also expressed bymyoblasts; CX3CL1 attracts M2 and also
induces the expression of pro-angiogenic factors, thus pro-
moting a microenvironmental shift toward a more regenera-
tive milieu. CX3CL1 also increases in human skeletal muscle
after exercise. Notably, an interaction between CCL2/CCR2
and CX3CL1/CX3CR1 chemokine systems in modulating
MF function during regeneration exists; the impaired MF
infiltration inCCL2-/-mice is rescued byCX3CR1 deficiency
through enhanced MF-dependent ApoE production, im-
proving MF phagocytic activity and compensating for de-
fective monocyte recruitment (7).
2. Cross-talk MF: FAPs. FAPs are multipotent mesen-
chymal progenitors of fibroblasts and adipocytes, residing in
the skeletal muscle interstitium (Fig. 15) and expressing
the surface markers platelet-derived growth factor receptor-
alpha and Sca1. Muscle regeneration is associated with an
early increase of FAPs that provide signals promoting MPCs
proliferation and differentiation, as observed in vivo (129,
149, 295, 352). For instance, IL-6 is upregulated in FAPs
from day 2 to 5 on muscle damage in mice and enhances
MPCs commitment (149). FAPs-derived Follistatin, a TGF-
b-superfamily ‘‘bio-neutralizer,’’ is crucial for proper myo-
tube formation, also improving muscle repair by increasing
MF and Pax7-positive cell density (228, 388). FAPs are also
responsible for ECM deposition during muscle regeneration
and, once muscle injury is fully repaired, FAPs return to
quiescence (16, 352).
On acute muscle injury, ECM deposition is a transient and
beneficial event supporting regeneration by providing a
scaffold for regenerating myofibers. In pathological condi-
tions, for example, muscular dystrophies, connective tissue
production is not reversible and leads to myofiber replace-
ment with fibrotic scars and fat deposition (Fig. 13A, Sirius)
(228, 284). The persistence of activated FAPs (also induced
by chronic inflammation) in the damaged muscle is associated
with increased collagen and pro-fibrotic factor production,
impairing the niche for proper SC activation and differentia-
tion and exacerbating the degenerative phenotype (59, 267).
Moreover, in injured muscles, FAPs are able to differentiate
into intramuscular adipocytes by undefined mechanisms (76).
Based on these considerations, the balance between FAPs
activation and FAPs apoptosis is crucial for determining the
extent of fibrosis, and the modulation of signaling pathways
that fine-tune this balance represents a potential therapeutic
approach (178).
FAPs are regulated by signals deriving from other resident
muscle cells whose behavior is also influenced by FAPs, in a
complex network of reciprocal functional interactions (16).
Chronic inflammation is a driving force of fibrosis,with several
cell types interplayingwith inflammatoryMF and contributing
to ECM accumulation (194); if M1 were to persist in damaged
muscles, this would contribute to fibrosis. As an example, fi-
brinogen, an ECM factor accumulated in muscles of mdx and
DMD patients, binds Mac-1 on the MF surface, thus upregu-
lating IL-1b and other pro-inflammatory cytokines. IL-1b in-
duces MF-dependent TGF-b expression, which increases
muscle fibroblasts collagen production (Fig. 16) (362); com-
promising fibrinogen-Mac1 interaction in mdx mice decreases
inflammation and improves muscle regeneration (361).
Recently, Lemos et al. demonstrated that MF-produced
soluble factors modulate ECM production and FAPs apo-
ptosis balance in murine models of acute and chronic muscle
damage (178). M1-produced TNFamediates FAPs apoptosis
that is necessary to reduce the number of FAPs and to limit
fibrosis. M2-produced TGF-b counteracts FAPs apoptosis,
triggering FAP differentiation in matrix-producing cells
(often referred to as a-SMA+myofibroblasts) providing ECM
components such as collagen isoforms, fibronectin, and la-
minin (16). Accordingly, blocking MF infiltration in regen-
erative murine muscles, by CCR2 ablation or by TNFa
expression inhibition, decreases FAPs apoptosis and in-
creases fibrotic tissue deposition (178).
Moreover, the tyrosine kinase inhibitors nilotinib and im-
atinib induce FAPs apoptosis, thereby reducing muscle fi-
brosis in mdx mice (136, 178). However, nilotinib-mediated
FAPs expansion inhibition also impairs proper muscle re-
generation in a murine model of acute muscle damage, since
it negatively affects SC expansion. This underlines the rele-
vance of the FAPs trophic supportive function exerted on SCs
(94). Besides MF, other inflammatory cells affect FAPs ac-
tivation during muscle regeneration; in particular,
eosinophil-secreted IL-4 induces FAPs proliferation, sup-
porting SC myogenesis and inhibiting FAPs differentiation
toward adipocytes (129).
Moreover, additional cell types other than FAPs are involved
in collagen deposition during the progression of chronicmuscle
diseases in mice, for example, pericytes (81), SCs undergo-
ing fibrogenic conversion (18, 273), and MF-dependent
endothelial-mesenchymal transition of endothelium-derived
progenitors (400).
We illustrated howMF recruitment to damaged muscles is
crucial for proper regeneration; in particular, a sequential
recruitment of different MF subtypes, with M1 followed by
M2, is necessary, since at each stage of regeneration, a re-
ciprocal cross-talk between muscle cells and differently ac-
tivated MF subsets mediated by soluble factors is required.
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However, the origin of M1 andM2 in the damaged area of the
skeletal muscle is still unclear.
VII. Metabolic Reprogramming of MF as a Potential
Therapeutical Approach to Improve Skeletal
Muscle Regeneration
The concept of MF reprogramming to promote anti-
inflammatory/regenerative M2 polarization that is able to
reduce inflammation is emerging as a new therapeutic im-
munometabolic approach to promote tissue healing and re-
duce inflammation in chronic inflammatory diseases such as
atherosclerosis, rheumatoid arthritis or multiple sclerosis, as
well as type 2 diabetes and obesity while improving aging
health. Vice versa, a reprogramming from tumor-promoting
M2 to anti-tumor M1 has been hypothesized as a therapy
against cancer [for references see Ref. (335)].
The study of the contribution of metabolic pathways and
the integration of local and systemic metabolism at the cel-
lular level in regulating immune cell development and
function is often referred to as immunometabolism; it further
includes studying the role of immune cells in metabolic ho-
meostasis. Manipulating immune cell metabolism can ben-
eficially enhance or temper the immune response, including
drivingMF polarization and function, useful for the potential
treatment of several diseases.
Compared with other strategies such as anti-inflammatory,
stem cells-based or antioxidant therapies, approaches based on
immunometabolism might have the unique advantage to both
reduce inflammation and, at the same time, enhance the tis-
sues’ regenerative potential, thus being particularly attractive
for chronic inflammatory, degenerative, and metabolic dis-
eases [reviewed in Refs. (133, 152)]. We will discuss how this
is particularly evident in skeletal muscle pathologies, includ-
ing degenerative myopathies, acute injury, and cachexia, as
well as in aging and regenerative medicine, where im-
munometabolismmodulation could treat inflammation as well
as improve regeneration. In particular, as mentioned earlier,
MF effect on muscle resident cells strongly depends on their
polarization status, which might be oriented by im-
munometabolic strategies (268).
A. Aging
M1-to-M2 polarization is influenced by a metabolic repro-
gramming that is induced by circulating FFA. In particular,
aged individuals’ FFA profile (characterized by an overall
circulating FFA increase) impairs M2 activation. Also, circu-
lating TNFa and IL-6 concentrations increase with age,
whereas IL-10 and TGF-b1 levels decrease, thus negatively
affecting skeletal muscle regeneration; therefore, acting on
MF metabolism might be beneficial (259).
In fact, some nutraceuticals can play a prominent role
in modulating skeletal muscle physiology (56); among
them, resveratrol, green tea, catechins, and b-hydroxy-b-
methylbutyrate improve SC function and regeneration in
muscles of aged mice after disuse, therefore contributing to
reducing sarcopenia (4, 15). In particular, resveratrol, also
considered an ‘‘exercise mimetic,’’ promotes murine M2
polarization in vitro; however, whether this mediates the
beneficial effect of resveratrol on skeletal muscle regenera-
tion or not needs to be clarified (53, 177, 292).
B. Duchenne muscular dystrophy
The balance between different MF subpopulations can
determine the progression of dystrophy in mdx mice; drugs
that are able to modify this balance might attenuate symp-
toms of muscular dystrophies. Anti-cytokine drugs favoring a
pro-regenerativeM2 phenotypemight be used, as observed in
murine models (333, 363). Also, corticosteroids are used with
some success to treat DMD, as observed in mice and humans;
however, the side effects of these drugs often outweigh their
benefits. Interestingly, HDAC inhibitors counteract disease
progression in mice by directly acting on muscle cells and
also by modulating MF polarization toward M2 (216).
Moreover, the FA EPA increases IL-10 expression and re-
duces IFNc levels, thus promoting M2 polarization, which
decreases inflammation in muscles of dystrophic mice (33).
Similarly, the SIRT1-activator resveratrol promotes M2 po-
larization, decreases inflammation, and increases utrophin
expression in mdx mice (112).
C. Regenerative medicine
Since regeneration of injured skeletal muscle depends on
M1-to-M2 phenotypic transition, in a tissue engineering
context, after implantation of the artificial device, the control
of M1-to-M2 progression might ensure a proper and timely
coordinated transition from the inflammatory to the healing
stage. Notably, it has recently been shown that degradation
products from the mammalian ECM biologic scaffolds used
for skeletal muscle reconstruction in regenerative medicine
promote alternative M2 polarization in in vitro mechanically
loaded murine MF, thus facilitating migration and myogen-
esis of MPCs in vivo and, ultimately, stimulating tissue repair
(82, 298, 314).
This IL-4-dependent pro-regenerative response is charac-
terized by cycolooxygenases-1 and -2 (COX-1/COX-2) ac-
tivity, which seems to be crucial to allow myogenesis and
collagen deposition in the damaged area (69). Resveratrol pro-
M2 activity has been suggested to promote vascularization in
tissue engineering applications (292, 349, 371). Also, trans-
plantation of acellular ECM scaffolds improves performance
of diseased muscles by promoting M2 polarization and acti-
vating MPCs (274, 278); however, other authors showed that,
conversely from vital grafts, devitalized grafts were unable to
promote an anti-inflammatory phenotype and regeneration
in vivo (100).
D. Obesity-insulin-resistance
Infiltrating pro-inflammatory MF characterize the adipose
tissue of obese individuals. Pro-inflammatory cytokines im-
pact on the surrounding tissue, which is associated to insulin
resistance. Moreover, HFD—mainly saturated FA—also
upregulates pro-inflammatory cytokines in skeletal muscle
and in skeletal muscle-infiltrating fat, which increase M1
polarization, further contributing to insulin resistance.
Therefore, metabolic modulators promoting M2 polarization
might be beneficial against insulin resistance, reducing ab-
errant glucose metabolism; palmitate-treated MF, as well as
myoblasts, downregulate miR-16, which is known to im-
pair M1 polarization.
Interestingly, MF over-expression of miR-16 enhances
insulin sensitivity in co-cultured murine myoblasts (330).
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In addition, a major contributor to the insulin-resistance
onset might be an altered and pro-oxidant cellular redox
state, which decreases NADPH levels that, in turn, activate
glucose-6-phosphate dehydrogenase (G6PDH), which is cru-
cial for NADPH maintenance. G6PDH activity is elevated in
adipose tissue and its over-expression causes insulin resistance
(176). In such a context, the anti-inflammatory and antioxidant
effects of M2 polarization might also help in reducing G6PDH
expression.
E. Cachexia
Some diseases, such as cancer and chronic heart failure
(CHF), are characterized by weight and skeletal muscle loss
that is referred to as cachexia (219, 368). In cachexia, an
increased systemic inflammatory state is associated with im-
paired myogenesis. In this context, the MF-reprogramming
approach might be useful to promote anti-inflammatory M2
polarization. Notably, anti-inflammatory therapies have
failed in counteracting cachexia (368). Therefore, the MF-
immunometabolic approach, which does not merely reduce
inflammation but also increases M2 activation, might po-
tentially promote muscle regeneration, limiting muscle loss
in cachexia. In this regard, we have recently found that the
metabolic modulator trimetazidine (TMZ) enhances myo-
genesis in cancer cachexia in mice (101), along with stimu-
lating M2 reprogramming in vitro (unpublished observations).
The MF-reprogramming approach against cachexia of
cardiac origin is supported by preclinical studies demon-
strating that M2 polarization (e.g., by EPA) is beneficial for
the myocardium, by reducing inflammation and promoting
cardiac healing after myocardial infarction (52, 111, 160,
326, 341). M2 polarization also counteracts systemic and
plaque inflammation in atherosclerotic disorders, thus re-
ducing CHF-associated factors (119, 299). As far as cancer-
induced cachexia is concerned, however, it must be taken into
account that, although being controversial, the most widely
proposed immunometabolic therapy against cancer implies
achieving M1 polarization to potentiate elimination of cancer
cells by TAM (335). Nevertheless, MF balance might have
different effects at different stages of tumor progression;
therefore, different time points in the reprogramming therapy
targeting either cancer or cachexia might also be considered.
F. Stimuli leading to metabolic
reprogramming-mediated MF polarization
Based on the earlier considerations, metabolic repro-
gramming stimuli modulating the M1/M2 balance might in-
terfere with skeletal muscle regeneration (300). In this
paragraph, we will be considering exercise, calorie restriction
(CR), and nutrients. Notably, it must be taken into account
that the chosen immunometabolic strategy must be selective
to MF without affecting metabolism of other cells. In fact,
besides MF, other resident muscle cells such as SCs undergo
metabolic remodeling during regeneration, switching from
FAO to glycolysis during the transition from quiescence to
proliferation. Moreover, metabolic reprogramming and
metabolic substrate utilization shift occur during cell differ-
entiation, when mitochondrial activity increases in most cell
types, including SCs.
1. Exercise. Moderate training modulates MF activa-
tion by stimulating M1-to-M2 polarization and exerting a
global anti-inflammatory effect in multiple organs [reviewed
in Refs. (109, 315)]. For example, in HFD-induced adipose
tissue of obese mice, exercise inhibits inflammation by ac-
celeratingM1-to-M2 polarization (157, 184, 193, 252). HFD-
driven M1 accumulation in white adipose tissue correlates
with insulin resistance in obese individuals (380); thanks to
its anti-inflammatory effect, exercise improves insulin sen-
sitivity. Also, in rats with nonalcoholic fatty liver disease,
moderate exercise increases hepatic M2 polarization (183).
Exercise suppresses IL-12 production, a stimulator of IFNc,
and reduces b2-adrenergic receptors in monocytes and MF
by modulating TLR4 signaling (315).
In skeletal muscle, physical activity stimulates the release of
myokines, among which cytokines are related to M1/M2 ratio
regulation (e.g., IL-6, TNFa, and IL-10) and are involved in
skeletal muscle regeneration. Exercise also triggers skeletal
muscle PGC-1a over-expression; PGC-1a coordinates energy
production, modulates myofiber metabolism, and regulates
exercise-induced phenotypic adaptation (91). As discussed
earlier, PGC-1a is upregulated in M2. PGC-1a also stimulates
M2 polarization by accelerating necrotic resolution and
counteracting fibrosis and muscle wasting in regenerating
murine skeletal muscle (72). Muscle regeneration is charac-
terized by a PGC-1a-dependent increased mitochondrial bio-
genesis and activity. PGC-1a also contributes to the fast-to-
slow myofiber conversion after muscle injury in mice, which
also influences damaged muscle recovery (80, 204, 369).
An anti-inflammatory role for PGC-1a has been reported in
cultured muscle cells with PGC-1a downregulating NF-jB
(72). Interestingly, exercise-induced PGC-1a upregulation
also plays an immunomodulatory role in skeletal muscle by
influencing cytokine expression; a PGC-1a-dependent B-
type natriuretic peptide (BNP) production in myofibers in-
duces M2 polarization, playing an anti-inflammatory and
pro-repair role. Therefore, BNP might be considered a novel
PGC-1a-dependent myokine mediating the cross-talk be-
tween tissue resident MF and skeletal muscle, as observed in
mice (96). In addition, the myokine irisin—upregulated by
exercise-induced PGC-1a—also suppresses inflammation
and stimulates M2 polarization in vitro (74).
Gordon et al. showed that resistance exercise enhances
M2-associated gene expression in human skeletal muscle
(113) and also reduces stress response, improves glucose
metabolism, mitochondrial activity, and OxPhos, thus being
protective for skeletal muscle (113). MF activation seems to
be relevant in maintaining skeletal muscle energy metabo-
lism, and the transcription factor C/EBPa controls both M1-
and M2 polarization; indeed, in the skeletal muscle of C/
EBPa–KO mice, mitochondrial respiration and FAO are re-
duced, consistently with an overall decreased exercise ca-
pacity of the animal (173).
The effect of exercise strongly depends on its modality,
intensity, and timing. Even when over-vigorous exercise re-
sults in damage, it still promotes M2 polarization and in-
creased myogenesis in skeletal muscle despite TNFa
increase, as observed in rats (215). Moreover, pO2 decreases
in skeletal muscle also on intense exercise, activating HIF,
which promotes capillarization and also acts on MF. M1-to-
M2 polarization influences myogenesis in vitro in co-cultures
of myoblasts with murine MF, whereas few data are
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available regarding the effect of MF polarization on myo-
genic cells in vivo as a consequence of physical exercise.
2. Calorie restriction. CR implies a negative energy bal-
ance stimulating adaptive metabolic changes with many
positive effects such as lifespan extension, delayed age-
associated disease onset, and improvement of metabolic
health. Studies of CR effects on MF polarization in mice
mainly concern white adipose tissue, where it has been
found that CR leads, by an IL-4Ra- and STAT6-dependent
signaling, to M2 polarization and metabolic improvement
(88). Mild CR contributes to transient M2 accumulation in
inflamed adipose tissue of obese subjects, where M2 sup-
ports remodeling of altered adipose tissue and enhances
the formation of healthy metabolically flexible adipocytes
that are able to control tissue FA levels, triglycerides/FA
cycling, and OxPhos (202).
Therefore, M1-to-M2 switching supports healthy adipose
tissue via the maintenance of metabolically beneficial MF. It
has also been found that CR promotesM2 activation in adipose
tissue, in both mice and humans, by increasing the appetite-
reducing neuropeptide-FF (NPFF) plasma levels. NPFF up-
regulates IL-4R-a, Arg1, IL-10, and alkylglycerol mono-
oxygenase; enhances p-STAT6 stability and, thus, M2
polarization (375).
3. Nutrients. MF-specific PPARc deletion leads to Ox-
Phos gene downregulation in skeletal muscle and also in the
liver, indicating that resident MF have a beneficial role in
regulating nutrient homeostasis (249). Besides resveratrol
(see sections V and VII), other nutrients impinging on me-
tabolism, such as amino acids, n-3 polyunsaturated FA (e.g.,
EPA or DHA), polyphenols, and vitamin D, improve skeletal
muscle regeneration by targeting immune and muscle cells
(73, 329). Indeed, the bioactive form of vitamin D3,
1,25(OH)2D3, inhibits M1 activation and promotes M2 ac-
tivation, an effect also observed in vivo (390) and being
mediated by PPARc (395). A critical role for the MF vitamin
D receptor in the inflammatory response to injury has also
been reported in mice (316). Moreover, although controver-
sial, a beneficial role for vitamin D in human skeletal muscle
regeneration has been proposed (32, 254, 266, 318).
Cocoa polyphenolic extract influences MFmetabolism by
promoting oxidative pathways and M2 polarization in human
MF in vitro (79). Pomegranate and its polyphenols promote
M1-to-M2 switch in murine MF (2), and grape seed-derived
polyphenols (proanthocyanidolic oligomers) accelerate
muscle regeneration in rats by activating SCs and by pro-
moting an anti-inflammatory switch (165). Interestingly,
polyamines are able to drive M2 polarization in murine MF
(354) and also to promote repair, fibrosis, and tissue re-
modeling in mice (272).
Sirtuins play a crucial role in skeletal muscle physiology;
indeed, SIRT1 inactivation in skeletal muscle impairs muscle
regeneration (293, 348). Based on the ability of some sirtuins
to modulate metabolism, promoting an M1-to-M2 transition
in vivo (see section V) (17, 75, 138, 153), a potential MF-
mediated effect of these deacetylases on skeletal muscle
regeneration might be worth further investigation. SIRT1 ac-
tivators are considered ‘‘exercise mimetics’’ and, as reported
earlier, other ‘‘exercise mimetics’’—that is, resveratrol and
AICAR—as well as metformin might drive M2 polarization
also in vivo (21, 44, 48, 239, 240).
More recently, the metabolic modulator TMZ (144) has
also been found to act as an ‘‘exercise mimetic’’; TMZ in-
creases oxidative metabolism while enhancing skeletal
muscle myogenesis (92, 101, 219). Moreover, TMZ reduces
the expression of pro-inflammatory cytokines in LPS-
stimulated MF and in a murine model of myocardial dys-
function (5, 45, 84), stimulating M2 reprogramming in vitro
(unpublished observations). This makes this drug and, pos-
sibly, other metabolic modulators (161, 345) promising
candidates for further investigation in the attempt to find new
treatments that are able to reprogram MF metabolism.
VIII. Conclusions
In conclusion, MFmight assume different features and play
different roles following specific activation routes, leading to
the acquisition of two extreme phenotypes that are referred to
as pro-inflammatoryM1 and anti-inflammmatory/regenerative
M2, which, simplistically, resume a much higher degree of
heterogeneity. M1 and M2 subsets are characterized by a
differential expression of cytokines, chemokines, and surface
markers, by different molecular signatures and transcriptional
regulation, and also by different metabolic features specifically
illustrated here. Importantly, differently polarized MF play
different roles, andMF are extremely plastic cells that are able
to readily switch their phenotype and function if properly
stimulated.
In particular, the role of differentially polarized MF in
skeletal muscle regeneration has been discussed here; coor-
dinated MF-phenotype transition is crucial to allow suc-
cessful muscle regeneration, and promoting M2 polarization
potentiates the tissues’ regenerative phase. Specifically, the
modulation of MF metabolism by immunometabolic strate-
gies might be an appealing tool, which is possibly able to
drive specific MF polarization routes and to open up a new
scenario in terms of rehabilitative protocol design since it
represents a potential therapeutic approach for several skel-
etal muscle conditions that might benefit from reduced in-
flammation and enhanced regeneration.
In the future, in-depth studies will hopefully disclose MF
heterogeneity and the cellular metabolic pathways associated
to specific MF polarization, thus identifying novel im-
munometabolic molecular targets and bolstering therapeutic
interventions for degenerative and immunometabolic diseases.
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Abbreviations Used
2DG¼ 2-deoxy-d-glucose
acetyl-CoA¼ acetyl coenzyme A
AICAR¼ 5-aminoimidazole-4-carboxamide-1-b-
4-ribofuranoside
AMPK¼ 5¢ adenosine monophosphate-activated
protein kinase
AP1¼ activator protein 1
Arg1¼ arginase-1
ASK1¼ apoptosis signal-regulating kinase 1
BMDM¼ bone marrow-derived MF
BNP¼B-type natriuretic peptide
CARKL¼ carbohydrate kinase-like
C/EBP¼CCAAT enhancer-binding protein
CHF¼ chronic heart failure
CIC¼ citrate carrier
COX¼ cytochrome c oxidase
COX-1/-2¼ cyclooxygenases 1 and 2
CR¼ calorie restriction
CTX¼ cardiotoxin
CXCL¼CXC chemokine ligand
DAMP¼ danger-associated molecular pattern
DMD¼Duchenne muscular dystrophy
DMF¼ dimethylfumarate
DTR¼ diphtheria toxin receptor
DUOX1/2¼ dual oxidases 1 and 2
ECM¼ extracellular matrix
eMyHC¼ embryonic myosin heavy chain
eNOS/NOS3¼ endothelial NO synthase, NO
synthase 3
EPA¼ eicosapentaenoic acid
ETC¼ electron transport chain
FA¼ fatty acids
FAO¼ free fatty acid b-oxidation
FAPs¼ fibroadipogenic progenitor cells
FATP1¼ fatty acid transport protein 1
FFA¼ free fatty acid
FGF¼ fibroblast growth factor
Fizz1¼ found in inflammatory zone 1
G6PDH¼ glucose-6-phosphate dehydrogenase
GAPDH¼ glyceraldeyhe phosphate dehydrogenase
GLUT4¼ glucose transporter type 4
GSH/GSSG¼ glutathione/oxidized glutathione
H2O2¼ hydrogen peroxide
H3K4¼ lysine 4 of histone 3
HDAC¼ histone deacetylase
HFD¼ high fat diet
HGF¼ hepatocyte growth factor
HIFs¼ hypoxia-inducible factors
HMGB1¼ high mobility group box 1
Idh1¼ isocitrate dehydrogenase 1
IFN¼ interferon
IGF-1¼ insulin-like growth factor-1
IKK¼ IkB kinase
IL¼ interleukin
IL-4Ra¼ IL-4 receptor-a
iNOS¼ inducible NO synthase
IRFs¼ IFN-regulatory factors
Irg1¼ Immunoresponsive gene 1
ISG¼ IFN-stimulated genes
KLF¼Kru¨ppel-like factors
KO¼ knockout
LPS¼ lipopolysaccharide
MF¼macrophages
MAPK¼mitogen-activated protein kinase
MCP1¼monocyte chemoattractant protein 1
M-CSF¼macrophage colony-stimulating factor
MDPs¼macrophage and dendritic cell
progenitors
MHC-II¼major histocompatibility complex II
MIP¼macrophage inflammatory protein
miRNAs¼microRNAs
MKP-1¼mitogen-activated protein kinase
phosphatase-1
MMF¼metabolite monomethyl fumarate
MMP2¼matrix metalloproteinase-2
MPCs¼muscle progenitor cells
MRFs¼muscle regulatory factors
mt-NOS¼mitochondrial NO synthase
mTOR¼mammalian target of rapamycin
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Abbreviations Used (cont.)
MyD88¼myeloid differentiation primary
response gene 88
MyHC¼myosin heavy chain
NFAT¼ nuclear factor of activated T-cells
NF-jB¼ nuclear factor jB
nNOS/NOS1: neuronal NO synthase, NO synthase 1
NO¼ nitric oxide
NOX¼NADPH-oxidase
NPFF¼ neuropeptide-FF
Nrf2¼ nuclear factor (erythroid-derived 2)-
like 2
OCR¼ oxygen consumption rate
OxPhos¼ oxidative phosphorylation
PAMPs¼ pathogen-associated molecular patterns
PDH¼ pyruvate dehydrogenase
PDK1¼ pyruvate dehydrogenase kinase 1
PFKFB3¼ 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3
PGC-1b¼PPARc-coactivator-1b
PHDs¼ prolyl hydroxylases
PI3K¼ phosphoinositide 3-kinase
PKM2¼ pyruvate kinase M2
pO2¼ oxygen partial pressure
PPARs¼ peroxisome proliferator-activated
receptors
PPP¼ pentose phosphate pathway
PRRs¼ pattern recognition receptors
RAGE¼ receptor for advanced glycation
end products
RANTES¼ regulated on activation, normal T cell
expressed and secreted
RELMa¼ resistin-like molecule alpha
RNS¼ reactive nitrogen species
ROS¼ reactive oxygen species
SCs¼ satellite cells
SDH¼ succinate dehydrogenase
SIRT¼ silent information regulator
SOCS¼ suppresor of cytokine signaling
STATs¼ signal transducers and activators
of transcription
SUCNR1/GPR91¼ succinate receptor 1/G-protein
coupled receptor-91
TAM¼ tumor-associated MF
TCA¼ tricarboxylic acid
TGF-b¼ transforming growth factor-b
Th¼T helper
TLR¼Toll-like receptor
TMZ¼ trimetazidine
TNFa¼ tumor necrosis factor-a
TORC¼mTOR complex
TRIF¼TIR-domain-containing
adapter-inducing interferon-b
TWEAK¼TNF-like weak inducer of apoptosis
UDP-GlcNAc¼UDP-N-acetylglucosamine
VEGF¼ vascular endothelial growth factor
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